

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/67955 A2

(51) International Patent Classification⁷: **A61B 5/055, A61M 5/14, G01R 33/28**

(21) International Application Number: **PCT/US01/07812**

(22) International Filing Date: **12 March 2001 (12.03.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/189,072 **13 March 2000 (13.03.2000) US**

(71) Applicants (*for all designated States except US*): **MEDI-PHYSICS, INC. [US/US]; 101 Carnegie Center, Princeton, NJ 08540 (US). UNIVERSITY OF VIRGINIA PATENT FOUNDATION [US/US]; 1224 West Main Street, Suite 1-110, Charlottesville, VA 22903 (US).**

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DRIEHUYS, Bastiaan [US/US]; 3625 Sunningdale Way, Durham, NC 27707 (US). FUJII, Dennis [US/US]; 106 Honeytree Court, Downingtown, PA 19335 (US). BROOKEMAN, James, R. [US/US]; 1800 Dairy Road, Charlottesville, VA 22903**

(74) Agent: **MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, NC 27627 (US).**

(81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **DIAGNOSTIC PROCEDURES USING DIRECT INJECTION OF GASEOUS HYPERPOLARIZED ^{129}Xe AND ASSOCIATED SYSTEMS AND PRODUCTS**

WO 01/67955 A2

(57) **Abstract:** A method of screening for pulmonary embolism uses gaseous phase polarized ^{129}Xe which is injected directly into the vasculature of a subject. The gaseous ^{129}Xe can be delivered in a controlled manner such that the gas substantially dissolves into the vasculature proximate to the injection site. Alternatively, the gas can be injected such that it remains as a gas in the bloodstream for a period of time (such as about 8-29 seconds). The injectable formulation of polarized ^{129}Xe gas is presented in small quantities of (preferably isotopically enriched) hyperpolarized ^{129}Xe and can provide high-quality vasculature MRI images or NMR spectroscopic signals with clinically useful signal resolution or intensity. One method injects the polarized ^{129}Xe as a gas into a vein and also directs another quantity of polarized gas into the subject via inhalation. In this embodiment, the perfusion uptake allows arterial signal information and the injection (venous side) allows venous signal information. The dual delivery is used to generate a combined introduction path with a more complete image signal of both the arterial and venous side of the pulmonary vasculature. In this NMR imaging method, the pulmonary embolism screening method can use the same NMR chest coil for the excitation and detection of the ^{129}Xe signals. The direct injection of small quantities of gas at particular sites along the vasculature targets specific target regions to provide increased signal intensity NMR images. The disclosure also includes related methods directed to other diagnostic vasculature regions physiological and conditions. Associated delivery and dispensing systems and methods, containers, and quantitative formulations of the polarized gas are also described.

DIAGNOSTIC PROCEDURES USING DIRECT INJECTION OF GASEOUS HYPERPOLARIZED ^{129}Xe AND ASSOCIATED SYSTEMS AND PRODUCTS

Related Applications

This application claims the benefit of priority from U.S. Provisional Application Serial No. 60/189,072 filed March 13, 2000, the contents of which are hereby incorporated by reference as if recited in full herein.

5

Field of the Invention

The present invention relates generally to magnetic resonance imaging ("MRI") and spectroscopy methods, and more particularly to the use of hyperpolarized ^{129}Xe in MRI and spectroscopy.

10

Background of the Invention

MRI using hyperpolarized noble gases has been demonstrated as a viable imaging modality. *See e.g.*, U.S. Patent 5,545,396 to Albert et al. The contents of this 15 patent are hereby incorporated by reference as if recited in full herein. Albert et al. proposed several techniques of introducing the hyperpolarized gas (either alone or in combination with another substance) to a subject, such as via direct injection, intravenous injection, and inhalation. *See also Biological magnetic resonance imaging using laser-polarized ^{129}Xe* , 370 Nature, pp. 199-201 (July 21, 1994). Other 20 researchers have since obtained relatively high-quality images of the lung using pulmonary ventilation of the lung with both hyperpolarized ^3He and ^{129}Xe . *See* J.R. MacFall, H.C. Charles, R.D. Black, H. Middleton, J. Swartz, B. Saam, B. Driehuys, C. Erickson, W. Happer, G. Cates, G.A. Johnson, and C.E. Ravin, "Human lung air spaces: Potential for MR imaging with hyperpolarized He-3," 25 Radiology 200, 553-558 (1996); and Mugler et al., *MR Imaging and spectroscopy using hyperpolarized ^{129}Xe gas: Preliminary human results*, 37 Mag. Res. Med., pp. 809-815 (1997). *See also* E.E. de Lange, J.P. Mugler, J.R. Brookeman, J. Knight-Scott, J. Truwit, C.D. Teates, T.M. Daniel, P.L. Bogorad, and G.D. Cates, "Lung Airspaces: MR Imaging Evaluation with Hyperpolarized Helium-3 Gas," Radiology

210, 851-857(1999); L.F. Donnelly, J.R. MacFall, H.P. McAdams, J.M. Majure, J. Smith, D.P. Frush, P. Bogorad, H.C. Charles, and C.E. Ravin, "Cystic Fibrosis: Combined Hyperpolarized ^3He -enhanced and Conventional Proton MR Imaging in the Lung -- Preliminary Observations," Radiology 212 (September 1999), 885-889
5 (1999); H.P. McAdams, S.M. Palmer, L.F. Donnelly, H.C. Charles, V.F. Tapson, and J.R. MacFall, "Hyperpolarized ^3He -Enhanced MR Imaging of Lung Transplant Recipients: Preliminary Results," AJR 173, 955-959 (1999).

In addition, due to the high solubility of ^{129}Xe in blood and tissues, vascular and tissue imaging using inhaled hyperpolarized ^{129}Xe has also been proposed.
10 Generally described, during inhalation delivery, a quantity of hyperpolarized ^{129}Xe is inhaled by a subject (a subject breathes in the ^{129}Xe gas) and the subject then holds his or her breath for a short period of time, *i.e.*, a "breath-hold" delivery. This inhaled ^{129}Xe gas volume then exits the lung space and is generally taken up by the pulmonary vessels and associated blood or pulmonary vasculature at a rate of approximately
15 0.3% per second. For example, for an inhaled quantity of about 1 liter of hyperpolarized ^{129}Xe , an estimated uptake is about 3 cubic centimeters per second or a total quantity of about 40 cubic centimeters of ^{129}Xe over about a 15 second breath-hold period. Accordingly, it has been noted that such uptake can be used to generate images of pulmonary vasculature or even organ systems more distant from the lungs.
20 See co-pending and co-assigned U.S. Patent Application Serial No. 09/271,476 to Driehuys et al, entitled *Methods for Imaging Pulmonary and Cardiac Vasculature and Evaluating Blood Flow Using Dissolved Polarized ^{129}Xe* . Although primarily directed to inhalation delivery, this application also proposes injection of ^{129}Xe to replace conventional radioactive tracers in perfusion imaging methods. The contents of this
25 application are hereby incorporated by reference as if recited in full herein.

Many researchers are also interested in the possibility of using inhaled ^{129}Xe for imaging white matter perfusion in the brain, renal perfusion, and the like. While the inhaled delivery ^{129}Xe methods are suitable, and indeed, preferable, for many MRI applications for several reasons, such as the non-invasive characteristics attendant
30 with such a delivery to a human subject, it may not be the most efficient method to deliver a sufficiently large dose to more distant (away from the pulmonary vasculature which is proximate to the lungs) target areas of interest. In addition, due to the

dilution of the inhaled ^{129}Xe along the perfusion delivery path, relatively large quantities of the hyperpolarized ^{129}Xe are typically inhaled in order to deliver a small fraction of the gas to the more distal target sites or organ systems. For example, the brain typically receives only about 13% of the total blood flow in the human body.

5 Thus, the estimated 40 cubic centimeter quantity of hyperpolarized ^{129}Xe taken up into the pulmonary vessels from the 1-liter inhalation dose can be reduced to only about 5 cubic centimeters by the time it reaches the brain.

Further, the hyperpolarized state of the gas is sensitive and can decay relatively quickly due to a number of relaxation mechanisms. Indeed, the relaxation time

10 (generally represented by a decay constant “ T_1 ”) of the ^{129}Xe in the blood, absent other external depolarizing factors, is estimated at $T_1=4.0$ seconds for venous blood and $T_1=6.4$ s for arterial blood at a magnetic field strength of about 1.5Tesla. *See* Wolber et al., *Spin-lattice relaxation of laser-polarized xenon in human blood*, 96 Proc. Natl. Acad. Sci. USA, pp. 3664-3669 (March 1999). (The more oxygenated arterial blood

15 provides increased polarization life over the relatively de-oxygenated venous blood). Therefore, for about a 5 second transit time (the time estimate for the uptaken hyperpolarized ^{129}Xe to travel to the brain from the pulmonary vessels), the ^{129}Xe polarization is reduced to about 37% of its original value. In addition, the relaxation time of the polarized ^{129}Xe in the lung itself is typically about 20-25 seconds due to

20 the presence of paramagnetic oxygen. Accordingly, ^{129}Xe taken up in the latter portion of the breath-hold cycle can decay to have only about 50% of the starting polarization (the polarization level at the initial portion of the breath hold cycle). Thus, generally stated, the average polarization of ^{129}Xe entering the pulmonary blood can be estimated to be at about 75% of the starting inhaled polarization value. Taking

25 these effects into account, the delivery to the brain of the inhaled ^{129}Xe can be estimated as about 1.4 cubic centimeters of the inhaled one-liter dose of ^{129}Xe polarized to the same level as the inhaled gas ($0.75 \times 0.37 \times 5\text{cc's}$). This dilution reduces delivery efficiency, *i.e.*, for remote target areas (such as the brain), the quantity of delivered ^{129}Xe is typically severely reduced to only about 0.14% of the

30 inhaled ^{129}Xe . Nonetheless, at least one researcher has made coarse images of ^{129}Xe in rat brains, but this inhalation administration delivery required large quantities of ^{129}Xe to be inhaled over a relatively long period of time. *See* Swanson et al., *Brain*

MRI with laser-polarized xenon in human blood, 38 Mag. Reson. Med., pp. 695-698 (1997). Unfortunately, the extended inhalation time period and/or associated large quantity dosage of the gas may not be desirable for certain clinical applications.

In an alternative delivery mode, Bifone et al. proposes the use of injectable 5 formulations to deliver hyperpolarized ^{129}Xe to regions of interest. Bifone et al., *NMR of laser polarized xenon in human blood*, 93 Proc. Natl. Acad. Sci. USA No. 23, pp. 12932-12936 (1996). Albert et al., *supra*, also describes such formulations. As described by Bifone et al., the injectable formulation consists of a biocompatible fluid in which hyperpolarized ^{129}Xe is dissolved. Such formulations can then be injected 10 intravenously to deliver hyperpolarized ^{129}Xe . For fluid injection, the formulation is described as preferably formed such that the biocompatible fluid has a high solubility for xenon while also providing a relatively long ^{129}Xe relaxation time. Examples of particular suggested biocompatible fluids include saline, lipid emulsions, and perfluorocarbon emulsions. Several researchers have shown images of fluid injectable 15 formulations. For example, Goodson et al. have shown images of ^{129}Xe dissolved in saline and injected into the hind leg of a rat. Goodson et al., *In vivo NMR and MRI Using Injection Delivery of Laser-Polarized Xenon*, 94 Proc. Natl. Acad. Sci. USA, pp. 14725-14729 (1997). Moeller et al. have also recently demonstrated venous angiography with hyperpolarized ^{129}Xe dissolved in Intralipid® solution. Moeller et. 20 al., *Magnetic Resonance Angiography with Hyperpolarized ^{129}Xe Dissolved in Lipid Emulsion*, 41 Mag. Res. Med. No. 5, pp. 1058-1064 (1999). The Intralipid® formulation purportedly has a xenon-Otswald solubility of about 0.6 and a ^{129}Xe relaxation time of 25 seconds in a magnetic field strength of 2.0 Tesla. In addition, 25 Wolber et al, have also recently demonstrated PFOB (perfluorooctyl bromide) emulsions which allegedly have increased transverse relaxation times and have purportedly provided improved imaging results. Wolber et al., *Perfluorocarbon Emulsions as Intravenous Delivery Media for Hyperpolarized Xenon*, 41 Mag. Res. Med., pp. 442-449 (1999). In yet another injection technique, Chawla et al., have proposed the use of hyperpolarized ^3He microbubbles suspended in a hexabrix 30 solution to perform angiography on rats. Chawla et al., *In Vivo Magnetic Resonance Vascular Imaging Using Laser-Polarized ^3He Microbubbles*, 95 Proc. Natl. Acad. Sci. USA, pp. 10832-10835 (1998).

Unfortunately, many injectable formulations can be unduly susceptible to handling and processing variables which can negatively impact the injectable formulation's commercial viability and/or clinical application. For example, the relatively short (and potentially magnetic-field dependent) relaxation time of the ^{129}Xe in the injectable solutions can require that the ^{129}Xe gas be dissolved into the biocompatible fluid relatively quickly and then subsequently rapidly injected to reduce the polarization loss of the formulation prior to injection. In addition, it may be difficult to predict the dissolution efficiency in a manner which can provide a reliable xenon dissolution concentration. Unreliable concentrations can, unfortunately, yield widely varying signal intensities, dose to dose. Further, because of the typically relatively quick decay associated with these formulations, a careful measurement of the final ^{129}Xe polarization just prior to injection to determine the post dissolution polarization may not be possible. Still further, because the ^{129}Xe is dissolved in a biocompatible fluid, sensitivity to the local *in vivo* environment such as blood oxygenation, tissue type, and the like, may be muted, reduced, or even non-existent. The use of such fluids or carrier agents to deliver ^{129}Xe to selected tissues or organs can also be difficult because of the high solubility of ^{129}Xe in the fluid compared to the tissues (its preferred affinity being to remain in the fluid rather than to migrate into the selected or targeted tissues).

In view of the foregoing, and despite the present efforts, there continues to be a need to improve the methods, products, and systems used to deliver hyperpolarized ^{129}Xe gas to a target *in vivo* imaging region of interest.

Objects and Summary of the Invention

It is therefore an object of the present invention to formulate and deliver ^{129}Xe *in vivo* in a manner which allows for high-quality mammalian tissue, organ, vascular, and/or angiographic MRI images using hyperpolarized gaseous ^{129}Xe .

It is another object of the present invention to provide a method of using reduced quantities of hyperpolarized gas while providing increased MRI image signal resolution.

It is an additional object of the present invention to provide methods

for obtaining improved quality NMR signals and/or MRI images of both the arterial and venous portions of the human vasculature and/or organs and/or systems using hyperpolarized ^{129}Xe .

It is a further object of the present invention to provide appropriate (bolus) 5 sized containers and associated delivery systems, apparatus, and methods which can reduce the depolarization of the hyperpolarized ^{129}Xe gas prior to and during delivery and can, thus, yield a clinically useful T_1 .

It is another object of the present invention to introduce a sufficient quantity of 10 hyperpolarized ^{129}Xe gas into the vasculature in a minimally intrusive manner to obtain MR spectroscopic signal and/or *in vivo* images.

It is yet another object of the present invention to facilitate the dissipation or dispersion of bubbles which may be injected into a subject.

It is an additional object of the present invention to provide imaging methods which may be able to screen for the presence of pulmonary emboli.

15 It is still another object of the invention to formulate ^{129}Xe as a pharmaceutical grade injectable formulation which can be monitored for polarization efficacy just prior to use with reduced decaying effect thereon.

It is another object of the present invention to provide NMR-based diagnostic 20 capability of vasculature (arterial and/or venous or organ) circulation related defects or emboli in a minimally or non-invasive and effective manner.

It is yet another object of the present invention to provide a diagnostic tool for the evaluation of pharmaceutical effectiveness on drugs directed to target regions or functions.

It is an additional object of the present invention to provide *in vivo* diagnostic 25 information regarding the cancerous condition of a solid mass.

It is another object of the present invention to prepare gas contacting surfaces and containers in a manner which reduces the amount of depolarizing oxygen therein while also employing purge gas which is suitable for injection.

It is still an additional object of the present invention to provide a way to 30 optimize capillary length for improved polarization life in containers configured to hold polarized noble gases such as ^{129}Xe and/or ^3He .

These and other objects of the present invention are provided by directly

injecting *in vivo* a predetermined quantity of hyperpolarized ^{129}Xe in gaseous phase to obtain MR based spectroscopic signal or images regarding a target site in the mammalian vasculature (or target organ, tissue, or region). The present invention also includes delivery and dispensing methods, systems, and product formulations, as well 5 as administration rates which may correspond to the use or injection site. In addition, the present invention provides polarization monitoring of the hyperpolarized gaseous ^{129}Xe which is formulated for direct injection *in vivo* into the vasculature for MR imaging and spectroscopic analysis.

In particular, a first aspect of the present invention is directed toward the 10 detection or screening for the presence of a pulmonary embolism. The method includes the step of positioning a subject having a pulmonary region and a blood circulation path including veins and arteries in a NMR system. The subject's pulmonary region has pulmonary veins and pulmonary arteries and associated vasculature defining a pulmonary portion of the circulation path. A quantity of 15 polarized gaseous ^{129}Xe is injected directly into at least one vein of the subject. NMR signal data associated with the polarized ^{129}Xe in the pulmonary region of the subject is obtained. The signal data includes information corresponding to the polarized gas introduced in the injecting step. An MRI image is generated having spatially coded visual representation of the NMR signal data. The presence of at least one condition 20 of blockage, restriction, abnormality, and substantially unobstructed free passage of the pulmonary circulation path is identified.

In one embodiment, the quantity of venous injected gaseous ^{129}Xe is less than about 100 cubic centimeters while quantity of arterial injected gaseous ^{129}Xe is less than about 14-20 cc's.

25 In another embodiment, in order facilitate bubble dissipation which may be associated with the injection of the ^{129}Xe gas within the subject, a quantity of liquid surfactant can be introduced *in vivo* temporally and spatially proximate to the gas injection (or concurrently at a location proximate to the gas injection) site. The injection pressure and/or the rate of injection can also be substantially controlled to 30 thereby control the delivery rate of the polarized gaseous ^{129}Xe into the injection site typically to about 1-3 cc/s or less for venous entry. The gas injection may be performed in a manner which reduces the bubble size associated with the injected gas

to preferably to less than about 5-10 μ m in diameter for certain embodiments (particularly for arterial injections) and less than about 75-150 μ m in diameter for venous injections.

In one embodiment, a second quantity of a polarized gas is introduced to a 5 subject during the same imaging session. That is, the first quantity is injected and an associated first image or signal acquisition can be obtained, and a second delivery and a second data or signal acquisition or image associated with the second quantity can be obtained. For example, the second delivery can be via inhalation of a hyperpolarized gas (either 3 He or 129 Xe, although for system equipment and coil 10 tuning reasons, 129 Xe gas is preferred) and the signal/image can be obtained after a short lapsed time period from the first signal/image (a time sufficient to clear traces of the polarized injected xenon from the target area). Additionally, or alternatively, the inhalation dose can be delivered prior to the injection of the polarized gas.

Alternatively, concurrent delivery of the injection and inhalation doses may be used. 15 It is anticipated that this may help with co-registration between the two images and may reduce image artifacts. Of course, the second delivery can be another injectable dose of 129 Xe gas, or an injection of a hyperpolarized gas product in liquid form (such as dissolved in a carrier liquid).

Another aspect of the present invention is directed toward a method of 20 obtaining MRI-based medical images. The method includes injecting directly into an injection site of a subject a first quantity of polarized 129 Xe in gaseous form and delivering a second quantity of polarized gas product to the subject within the same imaging session. The second delivery can be performed in a number of ways and with a number of polarized noble gas product formulations. For example, inhalation of a 25 polarized noble gas mixture (such as described for the embodiment above) or another injection (either of the 129 Xe gas directly or of a polarized noble gas product otherwise formulated such as in a carrier or liquid based injection formulation) at a point in time which is proximate to the injecting step. The second quantity is larger than the first (injected) quantity. An MRI image is then generated corresponding to the signal data 30 acquisition obtained via NMR excitation of the first and second quantities of polarized gas introduced in said injecting and delivering steps.

In certain embodiments, the injecting step injection site is a site associated

with the venous vasculature (such as a vein). In one embodiment, the delivering step is carried out by administering two separate polarized gas based doses. That is, the delivery step may be performed by injecting to second site in an artery and by inhaling a quantity of hyperpolarized gas. The second site or arterial injection quantity can be 5 in fluid or gas formulation. Thus, the inhalation based delivering step introduces the polarized gas via inhalation and the inhaled gas is subsequently directed into pulmonary arterial vasculature via perfusion uptake.

In another embodiment, the NMR signal data associated with both the injecting and delivering steps is processed in a manner which distinguishes NMR 10 signal information corresponding to gas versus dissolved gas signal information in the MRI image generating step. Alternatively, the MRI image-generating step is performed at a low magnetic field strength, and the NMR signal data is processed in a manner which combines or does not substantially distinguish between NMR signal data associated with excitation of the hyperpolarized gas whether in the gas phase or 15 the dissolved phase (the peaks associated with the polarized gas in the red blood cells and plasma in the blood overlap).

An additional aspect of the present invention is directed to a method of obtaining diagnostic images of the cranial region. The method includes the steps of injecting less than about 5 cc's (preferably about 1-2 cc's) of ^{129}Xe polarized gas into 20 an injection site in a carotid artery and dissolving the polarized ^{129}Xe gas into the vasculature proximate to the injection site. An NMR image is generated having signal intensity associated with the NMR excitation of the dissolved ^{129}Xe . The signal can be associated with the ^{129}Xe in one or more of the blood, grey matter, CSP, or white matter (to provide information corresponding to white matter perfusion typical of 25 desired neurological assessments). The excitation or response signal can be processed in a manner which allows the correlation to a particular region of interest, such as, for example, highlighting differences in chemical shift, T_2^* , T_1 , and the like as will be appreciated by one of skill in the art. The method can include, *inter alia*, the step of introducing, *in vivo*, a surfactant to facilitate bubble dissipation proximate to the 30 injection site.

In one embodiment, the injecting step is performed at a (controlled) rate and/or pressure sufficient to facilitate the dissolution of the gas in the vasculature proximate

to the injection site and/or in a manner which reduces the size of bubbles introduced therewith corresponding to the selected injection site (preferably to form smaller size 5 bubbles and smaller quantities of gas for arterial injections). An injection head with multiple orifices sized with a diameter of between about 1nm-50 μ m, and typically between about 0.01-10 μ m can be used and the gas may be mixed *in situ* with an emulsifier prior to delivery to facilitate a fine dispersion of gas into the body of the subject.

10 Another aspect of the present invention is directed toward a method of obtaining an MR image or NMR spectral data. The method includes injecting less than about 100 cc's of hyperpolarized gas *in vivo* into an injection site associated with the vasculature of a mammalian subject. An NMR image or spectral data is then generated corresponding to the injected quantity of hyperpolarized ^{129}Xe gas.

15 In one embodiment the method includes the step of administering the injection such that it remains substantially undissolved within the bloodstream for a period of time and such that it exhibits a T_1 in the bloodstream of at least eight seconds. Alternatively, the method can administer the injection such that it employs an introduction rate selected so that the gas is dissolved (at least partially) into the 20 vasculature proximate to the injection site and/or to reduce the size of bubbles associated with the injection.

In certain embodiments, the injection is performed by injecting the hyperpolarized ^{129}Xe into at least one predetermined injection site such as in an arm, leg, or at other externally accessible or viable injection locations. For example, the injection site can be chosen from the group consisting of a carotid artery, a pulmonary 5 artery, a renal artery, a hepatic artery, and a renal artery or the group consisting of a vein located in the arm (such as the central vein or peripheral vein), a jugular vein, a pulmonary vein, a hepatic vein, and a renal vein. In another preferred embodiment, the injecting step is performed by injecting the hyperpolarized ^{129}Xe into at least two different injection sites, preferably the injection sites corresponding to a vein or artery 10 which is externally accessible via injection of an IV or syringe needle such as in an arm, leg, or at other torso or other feasible locations.

The injection dose can be contained in a single-dose sized container. For arterial injections, the dose container can be sized and configured to hold less than

about 14-20 cc's of polarized ^{129}Xe gas therein. For venous injections, the dose
15 container can be sized and configured to hold less than about 100 cc's of polarized
 ^{129}Xe gas therein. The container can be a syringe configured with a primary body with
a wall having outer and inner surfaces, and the inner surface is formed from a material
which reduces contact induced polarization decay associated therewith. Preferably,
the syringe body is operably associated with a capillary stem and valve to control the
20 exit of gas from the syringe. The syringe body can also include an NMR excitation
coil mounted thereon. For delivery, it is preferred that a catheter is positioned in a
subject at the desired injection site (corresponding to the desired target image region
in the subject). The catheter can include or be operably associated with a frit or
needle which is formed or coated with a polarization friendly material (such as a gold
25 plated or aluminum needle). The frit or needle may also be configured and sized to
reduce the bubble size to at or below about a 10 micron diameter at injection. This
reduced bubble size may be particularly suitable for arterial injection sites.

In certain embodiments, an injection system for administering polarized gas to
a subject can include (a) a polarized noble gas supply; (b) a catheter configured and
30 sized for intravenous or intrarterial placement in a subject in fluid communication
with the supply of polarized noble gas; and (c) an injection head positioned in a distal
portion of the catheter. The injection head can comprise multiple orifices which are
configured so that, in operation, hyperpolarized gas flows therethrough and out of the
catheter into the subject. The orifices can be sized with a width which is between
35 about 1nm-50 μm , and typically between about 0.01-10 μm .

In certain embodiments, the system can include an additive source (such as an
emulsifier source) and a mixing chamber positioned intermediate the orifices and the
additive or emulsifier and polarized gas sources to mix the hyperpolarized gas and the
additive or emulsifier prior to expulsion from the injector head orifices (typically it is
40 mixed in situ as the gas flows away from the gas source toward the exit orifice(s) in
the injection head). The system may also include a heating or cooling means to
promote the generation of a fine dispersion of gas mixture from the injection head
(which typically resides in an IV inserted into the body).

In preparing the syringe, catheter, injection system, and/or conduit associated
45 therewith for use according to the present invention, CO_2 can be employed as a purge

gas to prepare the container and reduce the likelihood of introducing nitrogen via injection into a subject (potentially leaving residual or traces of CO₂ rather than nitrogen which has been conventionally used to prepare the polarized gas containers). As such, the injectable ¹²⁹Xe may include small quantities or traces of CO₂ therewith.

50 The system may include a resilient dose bag having external walls which are responsive to the application of pressure thereagainst and a quantity of hyperpolarized gas held in the dose bag along with an inflatable bladder which is sized and configured to receive at least a portion of the dose bag therein. In operation, the inflatable bladder is inflated to press against the dose bag external walls to thereby 55 expel a quantity of the hyperpolarized gas from the dose bag.

In one embodiment, the present invention is configured to employ a dual path hyperpolarized gas product delivery system. For a manual presentation and delivery, a technician can deliver the ¹²⁹Xe (inject) and then trigger a switch in the MRI unit indicating that the delivery is complete. The MRI unit, in response to activation of the 60 switch, can initiate the imaging procedure such that it commences within the required polarization life at the target-imaging region. The MRI unit can also have a timer operably associated therewith which can alert the technician when it is acceptable to deliver the inhalation dose. The inhalation dose can be an optional delivery which is withheld if no reasonable indicia of perfusion deficits are indicated by NMR signal 65 obtained based on the injected dose. Of course, the injection dose and the inhalation dose order can be reversed, wherein the injection dose is administered second. In addition, automated delivery and sequencing methods can also be employed as will be appreciated by one of skill in the art.

For concurrent delivery, the system can include a user audible and/or visual 70 alert which is responsive to one or more of the dispensing systems (it is activated when a gas or liquid polarized product commences delivery at an IV or inhalation or other administration) that allows the dispensing of more than one dose/path of gas (such as the inhaled and injected gas) to be timed or substantially concurrently (or at a predetermined or desired interval) administered. This can facilitate the effective 75 delivery and initiation of imaging sequences which can be important due to the limited polarization life of the polarized gas product in the blood.

An additional aspect of the present invention is a method of evaluating the

efficacy of targeted drug therapy, comprising the steps of delivering a quantity of a predetermined gene treatment preparation or pharmaceutical drug *in vivo* into a
80 mammalian subject having a target site and a treatment condition; injecting a predetermined quantity of gaseous phase hyperpolarized ^{129}Xe *in vivo* into a mammalian subject such that the hyperpolarized gas is delivered to the target site in gaseous or dissolved form; generating a NMR image or spectroscopic signal of the target site associated with the injected hyperpolarized ^{129}Xe gas; and evaluating the
85 NMR image or spectroscopic signal to evaluate the efficacy of the gene treatment or drug on the treatment condition administered in the delivering step.

In one embodiment, the method further comprises the step of acquiring at least two sets of data, the data representing two temporally spaced apart points in time, to evaluate if the treatment condition is influenced by the drug or gene therapy
90 introduced in the delivering step. Of course, the evaluation may be performed without regard to toxicity and/or survival if done in connection with animal research.

Another aspect of the invention is a method of determining the presence of cancerous tissue, comprising the steps of delivering a quantity of a pharmaceutical drug *in vivo* into a mammalian subject having a target site associated with a suspect
95 mass or tissue abnormality; injecting a quantity of gaseous hyperpolarized ^{129}Xe *in vivo* into a mammalian subject such that the hyperpolarized gas is delivered to the target site; generating a NMR image or spectroscopic signal of the target site corresponding to the injected hyperpolarized ^{129}Xe gas; and evaluating the NMR image or signal for the presence or absence of signature patterns in the generated
100 image or signal associated with the presence or absence of cancer.

An additional aspect of the present invention is an injectable ^{129}Xe gas product, the ^{129}Xe gas product formulated as a sterile non-toxic hyperpolarized gas formulation which consists essentially of isotopically enriched ^{129}Xe in gaseous phase which is injected *in vivo* in a quantity of less than about 20-100 cubic centimeters.

105 Similarly, another aspect of the present invention is an injectable ^{129}Xe gas pharmaceutical grade product, the product formulated as a sterile non-toxic product which consists essentially of ^{129}Xe in gaseous phase and traces of CO_2 , wherein the injectable gas product is configured to be dispensed *in vivo*.

The present invention is advantageous because relatively small quantities of

(preferably isotopically enriched) hyperpolarized ^{129}Xe gas with relatively predictable or known polarization levels can provide high-quality MRI images or spectroscopy data with clinically useful signal resolution for *in vivo* tissue and/or vasculature.

Indeed, in one preferred embodiment, the pulmonary embolism detection method can 5 be performed as a relatively quick screening method typically with high quality diagnostic information about the circulatory path, such as in under about 15 minutes. In this embodiment, it is preferred that both an inhalation (ventilation) and injection delivery of hyperpolarized gas are used to generate a combined (dual) introduction path. That is, inhalation can provide a first order image or ventilation image of the 10 lungs. However, the gas migrates into the vasculature and/or is uptaken by the blood stream and, thus, is introduced into a pulmonary vein(s). This uptake can provide MRI or NMR venous spectra/information of the venous side of the circulatory system. In contrast, the injection into a venous pathway can yield NMR arterial signal information (generally described, the ^{129}Xe gas injected in a vein travels/flows to the 15 right side of the heart and then into a pulmonary artery). Therefore, the dual introduction path can provide a more complete image/ signal of both the arterial and venous side of the pulmonary vasculature. Conveniently, by using polarized ^{129}Xe gas both as the inhalation and injection NMR medium, the pulmonary embolism screening method can use the same NMR chest coil for the excitation and detection of the ^{129}Xe 20 signals associated with the inhaled/perfusion dose and the injected dose.

Of course, direct injection of ^{129}Xe polarized gas to a particular target site such as a tumor can allow for additional diagnostic information over many conventional procedures. For example, *in vivo* cancerous tumors can be characterized by the presence of increased random blood vessel growth (a condition known as 25 angiogenesis). This is in contrast to benign cysts. Taking advantage of this characteristic and the NMR signal information available using direct ^{129}Xe polarized gas injection, the present invention can analyze *in vivo* a target in an organ such as a tumor in a breast. For example, a needle can be inserted or injected to the suspect region in the breast via conventional MR guided needle placement and ^{129}Xe can be 30 released thereat (along with or in lieu of removing biopsy materials). Signature peaks in spectroscopy signals (or improved image resolution attributed to the hyperpolarized ^{129}Xe signal) can indicate the presence of cancer via the increased peak in the signal

due to the increased blood (and the injected xenon's solubility therewith). Of course, other contrast mechanisms like chemical shift, T_2^* , diffusion, T_1 , and the like, can also be employed to exploit the ^{129}Xe NMR image or spectroscopic signal in the tumor.

5 In addition, the present invention preferably employs a reliable quantitative concentration and/or predictable injection quantity. This predictable concentration of polarized gas can provide more predictable and reliable signal intensity for the associated MRI image, which, in turn, makes the method clinically useful as well as easier to correlate, patient to patient, or in a single patient over time. Preferably, the
10 injectable quantity is selected to correspond to the introduction (injection) site; the venous side can use increased quantities compared to the arterial side (the venous side injections preferably sized at about 100 cc's or less while the arterial injections are typically sized at about 14-20 cc's or less).

15 In addition, the gas is preferably injected in a manner which facilitates reduced size bubbles introduced or formed by the injecting of gas. Controlling one or more of bubble size based on its responsive parameters, the quantity of gas administered, and/or injection rate (release) (as well as the configuration of the nozzle or exit chamber) of the gas can assure that the gaseous delivery to vasculature is done in an effective manner.

20 In one embodiment, the *in vivo* introduction of a suitable surfactant temporally and spatially proximate to (preferably upstream) the actual injection of the gas (temporally before or concurrent to the gas injection) can facilitate the dissipation or decreased size of injected bubbles in the venous and/or arterial system (depending on the injection site).

25 Further, the present invention recognizes that in order to allow the injected xenon gas sufficient time to enter the pulmonary vasculature, the NMR scanning is preferably delayed a sufficient amount of time after injection to allow for same, typically about 5-10 seconds post-injection. On the upper time limit, the NMR scan is also preferably performed within about one minute post-injection (and preferably 30
30 seconds after injection) as the polarization level will decay to an undesirable level relatively shortly after introduction into the body. Of course, multiple serially

successive quantities of administered injection doses can be administered during the imaging session for obtaining a plurality of sequential or multi-shot images.

The dispensing methods, containers, and other apparatus of the present invention are advantageously configured to facilitate a longer T_1 for the polarized gas and, thus, to promote a single-bolus sized formulation with a predictable level of polarization in a hyperpolarized product. Further, the ^{129}Xe injectable gas product can be delivered and formulated in a way which allows the gas to be analyzed to determine its polarization level prior to delivery to thereby confirm the efficacy of the product just prior to (or in a preferred temporally appropriate point prior to) 10 introduction into the patient.

Further, the present invention provides methods for sizing the length of a capillary stem on a container having a primary hyperpolarized gas holding chamber with a volume, the capillary stem having a volume which is substantially less than that of the gas holding chamber and includes a wall defining a flow channel aperture 15 having a radius or width and a length. The wall has a gas-contacting surface formed of a material having a relaxivity value for a selected hyperpolarized gas associated therewith. The method comprises the steps of defining a capillary stem aperture size; establishing a relaxivity value for the material forming the capillary wall; and calculating an optimal capillary stem length. Similarly, the present invention can 20 configure containers with capillary lengths chosen to increase the polarized life of the gas held therein.

Brief Description of the Drawings

Figure 1A is a schematic illustration of the human circulatory system 25 illustrating the venous and arterial portions thereof. The deoxygenated blood is represented by the lighter/white regions and the oxygenated blood is represented by the darkened regions.

Figure 1B is a schematic illustration of preferred anatomic injection sites 30 associated with MRI angiographic imaging regions according to the present invention. Region “A” represents the cranium, region “B” represents the lower extremities, region “C” represents the pulmonary vasculature, region “D” represents the renal portion of the circulation system or vasculature, and region “E” represents the hepatic

portion of the vasculature. Exemplary injection sites or delivery paths associated with the imaging regions are noted by the numeric subscript. For example, for pulmonary vasculature imaging region represented by the letter "C", a first injection site C_1 and a second ventilation delivery path C_2 are shown according to the present invention. In 5 contrast, the remainder of the regions are shown with one or more injection sites.

Figure 2 is a schematic illustration of a MRI system for pulmonary embolism screening according to a preferred embodiment of the present invention. As shown, the subject is receiving two separate doses of hyperpolarized gas, one of which is injected ^{129}Xe gas and one of which is inhaled gas (ventilated).

10 **Figures 3A** is a cross-sectional view of a vein.

Figure 3B is a cross-sectional view of an artery.

Figure 4 is a side view of different sized blood vessels illustrating different flow rates corresponding to diameter of the vessel at a particular pressure.

15 **Figure 5** is a schematic illustration of a controlled gas delivery system according to the present invention.

Figure 6 is a side view of an alternate controlled gas delivery system according to the present invention.

Figure 7A is a section view of the syringe taken along the line drawn as 7A-7A in **Figure 6**.

20 **Figure 7B** is a side view of a hyperpolarized gas injection device with a NMR excitation coil mounted thereon according to the present invention.

25 **Figures 8A and 8B** are perspective views of yet another alternative gas delivery system according to the present invention. **Figure 8A** illustrates the gas container with an inflatable inner membrane member. **Figure 8B** illustrates the inner membrane member expanded to expel or force a quantity of hyperpolarized gas out of the chamber. **Figure 8B** also illustrates a NMR monitor coil positioned to detect the polarization level of the gas, preferably just prior to dispensing into the subject.

Figure 8C is an enlarged end view of the exit surface of an injector head according to embodiments of the present invention.

30 **Figure 8D** is a schematic drawing of an injection system according to embodiments of the present invention.

Figure 8E is a schematic drawing of an alternative injection system according to embodiments of the present invention.

Figure 8F is an enlarged sectional view illustrating at least two separate flow channels and a mixing chamber upstream of gas outlet ports according to 5 embodiments of the present invention.

Figure 8G is a greatly enlarged partial side view of an injection head having a convergent nozzle configuration according to embodiments of the present invention.

Figure 8H is a greatly enlarged partial sectional side view of an end portion of an injection head according to embodiments of the present invention.

10 **Figure 8I** is a greatly enlarged partial sectional side view of an alternate configuration of an end portion of an injection head according to embodiments of the present invention.

15 **Figure 9** is a graph of a timing sequence of a quantity of injected gas and a MRI pulse imaging sequence according to a preferred embodiment of the present invention.

20 **Figures 10A-10P** are graphs of NMR spectra obtained about every 0.5 seconds via a whole body imager based on about a 3 cc polarized ^{129}Xe gas injection into the vein of a rabbit (total of elapsed time from **Figure 10A** to **10P** being about 8 seconds). The graphs illustrate that the gas remained substantially in the gas phase 25 (substantially insoluble as it traveled through the bloodstream during the image acquisition). The signal strength at 8 seconds (**Figure 10P**) being about 0.65 that of the original signal (**Figure 10A**).

25 **Figure 11** is a graph which illustrates a relationship which can assess an increased, and preferably, optimum capillary length for containers housing ^{129}Xe . The graph shows a maximum or optimal T_1 obtained at particular length and that for larger or smaller lengths, the T_1 is reduced over the T_1 obtainable at the optimal length. The same relationship can be used to determine capillary lengths for ^3He and these lengths will be substantially longer for similar T_1 's and similarly sized containers and stem radii.

30

Detailed Description of Preferred Embodiments of the Invention

The present invention now will be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; 5 rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Like numbers refer to like elements throughout. In the figures, certain layers, regions, or components may be exaggerated or enlarged for clarity.

As known to those of skill in the art, polarized gases are collected, frozen, 10 thawed, and used in MRI applications. For ease of description, the term "frozen polarized gas" means that the polarized gas has been frozen into a solid state. The term "liquid polarized gas" means that the polarized gas has been or is being liquefied into a liquid state. The term "gaseous" hyperpolarized ¹²⁹Xe indicates the gaseous phase of the "hyperpolarized ¹²⁹Xe gas". Thus, although each term includes the word 15 "gas", this word is used to name and descriptively track the gas which is produced via a hyperpolarizer to obtain a polarized "gas" product. Thus, as used herein, the term "gas" has been used in certain places to descriptively indicate a hyperpolarized noble gas product and may be used with modifiers such as solid, frozen, and liquid to describe the state or phase of that product.

20 Various techniques have been employed to accumulate and capture polarized gases. For example, U.S. Patent No. 5,642,625 to Cates et al., describes a high volume hyperpolarizer for spin polarized noble gas and U.S. Patent No. 5,809,801 to Cates et al. describes a cryogenic accumulator for spin-polarized ¹²⁹Xe. U.S. Patent No. 6,079,213 to Driehuys et al., entitled "Methods of Collecting, Thawing, and 25 Extending the Useful Life of Polarized Gases and Associated Apparatus," describes an improved accumulator, collection and thaw methods, and xenon gas heating means. The disclosures of these documents are hereby incorporated by reference as if recited in full herein.

As used herein, the terms "hyperpolarize", "polarize", and the like, mean to 30 artificially enhance the polarization of certain noble gas nuclei over the natural or equilibrium levels. Such an increase is desirable because it allows stronger imaging signals corresponding to better MRI (and spectroscopy) images of the substance and a

targeted area of the body. As is known by those of skill in the art, hyperpolarization can be induced by spin-exchange with an optically pumped alkali-metal vapor or alternatively by metastability exchange. *See* Albert et al., U.S. Patent No. 5,545,396. Other methods may also be used, such as dynamic nuclear polarization ("DNP") and 5 "brute force" methods which propose to cool the ^3He or ^{129}Xe to very low temperatures and then expose them to very high magnetic fields to enhance the thermal equilibrium polarization.

Generally stated, the present invention recognizes that direct gaseous injection of hyperpolarized ^{129}Xe can be a viable, safe, and effective delivery method when the 10 gas is formulated and delivered in a manner which reduces the potential for formation of emboli within the vasculature. Unlike many previous injectable formulations, the present invention employs a gaseous formulation of inert polarized (preferably "isotopically enriched" polarized ^{129}Xe gas as will be discussed further below) ^{129}Xe which is packaged in a polarization friendly (increased longer relaxation life) 15 container or syringe to provide an injectable pharmaceutical grade gas phase product. The gas phase injectable formulated hyperpolarized ^{129}Xe can be an effective image enhancing product when delivered at a controlled rate and/or quantity with a predictable polarization level which can provide improved image resolution and/or diagnostic capability without the need for additional liquid carrier agents and mixing. 20 Direct gaseous injection has many advantages that can not only simplify the diagnostic procedure, it can also restore the sensitivity of ^{129}Xe to its environment and can improve the delivery efficiency of polarized ^{129}Xe to target tissues. The gaseous injection can be performed such that it remains substantially non-dissolved in the bloodstream over about 8-10 seconds from the time of injection, or can be performed 25 such that it is at least partially, and even substantially, dissolved proximate to the injection site or within a short period from the time of injection (*i.e.*, less than about 2-4 seconds).

Further, in certain embodiments the gaseous formulation can eliminate the use of an external fluid-mixing step. Still further, the hyperpolarized ^{129}Xe can be 30 contained in a specialized gas syringe with increased relaxation times as will be discussed further below. In certain embodiments, the degree of polarization is measured via an NMR coil located on the dispensing container itself which can be

utilized just prior to administration. Thus, the NMR signal strength can be more accurately/reliably correlated to the polarization level and also the administration can be performed in a relatively calm, relaxed manner, without the impending threat and constraints of rapid decay elicit in many conventional short T₁ formulations.

5 Referring now to **Figure 1A**, a human circulatory system 10 is schematically illustrated. The oxygenated blood within the vasculature is represented by the darker regions while the deoxygenated blood is represented by the white or lighter regions.

As used herein the term "vasculature" includes boundary tissue, cells, membranes, and blood vessels such as capillaries, venules, veins, arteries, arterioles, 10 and the like associated with the circulatory system and blood flow path and/or channels of blood. Typically, as shown in cross sectional views in **Figures 3A** and **3B**, the artery flow channels 30a are smaller and more rigid and round compared to the vein flow channels 30v.

The gaseous ¹²⁹Xe injection of the present invention has some similarities to a 15 technique presently used, called digital subtraction (DSA) CO₂ angiography. Generally described, in this conventional procedure, CO₂ is rapidly injected to displace a portion of the blood. An X-ray image is taken quickly after injection. Where the CO₂ has displaced the blood, there is reduced X-ray opacity and the image 20 appears brighter. Typically, a second X-ray is taken without CO₂ injection and the two images are digitally subtracted to show the contrast. CO₂ DSA is used instead of traditional iodinated contrast agents because of the "nephrotoxicity" of iodine-based contrast agents. The volumes of CO₂ injected range from roughly 10cc's to 50cc's (the larger quantity for larger blood vessels). In addition, the injection rate is quite 25 rapid (10ml/s to 100ml/sec) inasmuch as contrast only results from the displacement of blood. Generally stated, after injection, CO₂ is efficiently dissolved into the blood and exhaled upon passage through the pulmonary capillary bed. Stated differently, CO₂ exits the blood into the lung alveoli via diffusion through pulmonary capillary. A review of this technique has been presented by Hawkins and co-workers. Kerns et al., *Carbon Dioxide Digital Subtraction Angiography: Expanding Applications and 30 Technical Evolution*, 164 Am. Jnl. Radiology, pp. 735-741 (1995).

The feasibility of gaseous ¹²⁹Xe injection, particularly for arterial injections, may appear problematic. For example, it is known that arterial injections of air can

lead to an undesirable air embolus. Although with intravenous (IV) injection the introduction of air is less of a concern, great care is typically taken to avoid such occurrences. The injection of CO₂ is successful because of its high solubility in blood and the body's unique ability to remove it. The solubility of CO₂ in blood and plasma 5 can be difficult to measure because it is chemically metabolized. However, its solubility in water is 0.63 and it has been measured in RBC (red blood cell) ghosts to be about 1.0. **Table 1** below shows the solubilities of other relevant gases in water plasma and blood.

10

Table 1
Solubilities of Gases

Gas	Water	Plasma	Blood	Other
He	0.0098	0.0086	0.0094	0.0105 (lung)
N ₂	0.0143	0.0134	0.0148	0.109 (RBC ghosts)
O ₂	0.0271	0.0243	0.0261	0.13 (RBC ghosts)
CO ₂	0.631	-	-	1.0 (RBC ghosts)
Xe	0.089	0.105	0.167	0.181 (liver)

15

As CO₂ in plasma and blood are metabolized before the measurements can be obtained, no numbers are listed for these entries in **Table 1**. Nonetheless, it is believed that the solubility that is of primary interest for the discussion herein and that the CO₂ metabolism can be disregarded for the purposes of this comparison.

Table 2 below shows the solubilities of these gases relative to CO₂ (*i.e.*, the relative solubility "S_r" is represented by the ratio of:

(Solubility of named gas in water)/(Solubility of CO₂in water)).

20

Table 2
Relative Solubility (S_r)

Gas	S _r (relative)
CO ₂	1
Xe	0.14
O ₂	0.043
N ₂	0.023
He	0.016

Table 2 illustrates the higher solubility of xenon compared to the major constituents of air (O₂ and N₂) but also shows that CO₂ is considerably more soluble

than xenon. Therefore, the present invention recognizes that direct gaseous injection of polarized ^{129}Xe can be a useful *in vivo* diagnostic NMR imaging tool and also recognizes that proper sizing of the injectable quantities and/or the injection rates are important considerations for achieving same. Accordingly, the present invention

5 provides a maximum preferred arterial xenon injection volume by comparing the solubilities of xenon and CO_2 . Maximum CO_2 injection volumes are typically limited to about 50-100 cc's of gas. By taking the relative solubilities above into consideration, the maximum xenon injections can be predicted to be about 0.14 times the quantity or volumes of CO_2 . Thus, particularly for arterial injection sites, for a

10 CO_2 volume of 100 cc's, the xenon injection volume is preferably limited to about 14 -20 cc's. For the smaller range of injected CO_2 , such as a 10 cc injection volume, a 1.4 -2.0 cc volume of polarized ^{129}Xe gas is preferably dispensed according to the present invention.

In contrast, for non-arterial sites, such as for venous injection sites, a larger

15 injection quantity may be tolerated. That is, it is known that the introduction of air into venous sites which is on the order of 300-400 cc's can be particularly troublesome and even potentially fatal. Xenon, although less soluble in blood than CO_2 , is about 10 times more soluble than air (*i.e.*, it can dissolve faster in blood than air). Thus, even with a safety factor, the venous site injections can be typically sized

20 at quantities in the range of about 100 cc's, although preferably sized at less than 100 cc's. Of course, such injection volumes also depend on the vessel type and size being injected into.

Along with the quantity of the gas formulated for injection, the generated

25 bubble size and/or bubble dissipation can be important considerations for *in vivo* applications, particularly for arterial injection sites. In certain embodiments, a surfactant can be injected proximate in time and location to the gas injection site to either help dissipate the size of the bubble and/or to lower the blood surface tension. Surfactants have been studied by van Blankenstein et al. to aid in the recovery from venous air embolism. *See* J.H. van Blankenstein et al., *Cardiac Depression after Experimental Air Embolism in Pigs: Role of Addition of a Surface-Active Agent*, 34 Cardiovascular Research, pp. 473-482 (1997). In this study, air bubbles with a diameter of about 150 μm were injected into the left anterior descending coronary

artery in the presence or absence of antifoam. A 1:250 dilution of silicone antifoam 1510 EU (from Dow Corning) in pure water was used. The study indicates that the *in vivo* introduction of surfactants can reduce bubble dissipation time in blood.

It is contemplated by certain embodiments of the present invention that any 5 suitable *in vivo* physiological compatible or acceptable surfactant can be employed whether of natural (human or bovine) or synthetic origin, and/or combinations thereof. Suitable physiologically acceptable formulations are known to those of skill in the art. *See e.g.*, U.S. Patent No. 4,826,821 to Clements, U.S. Patent No. 4,312,860 to Clements, and U.S. Patent No. 5,309,903 to Long (all discussing the use of surfactants 10 *in vivo* for respiratory distress syndrome). These disclosures are hereby incorporated by reference as if recited in full herein. *See also* Horbar et al., *A Multicenter Randomized, Placebo-controlled Trial of Surfactant Therapy for Respiratory Distress Syndrome*, 320 The New England Jnl. of Med., No. 15, pp. 959-965 (April 13, 1989) (discussing organic solvent extract of cow-lung fortified with dipalmitoylphosphatidylcholine known as "SURVANTA" from Abbott Laboratories in Chicago, 15 Illinois). Preferably, the surfactant is also chosen such that it is substantially non-depolarizing to the hyperpolarized state of the gas. The surfactant may be delivered via injection or insertion into the body proximate to the target gas injection site such that it facilitates bubble dissipation or reduces blood surface tension while also being 20 substantially non-depolarizing to the polarized state of the gas (to help reduce the formation of emboli attributed to the injected gas).

As briefly discussed above, the injection of the gas can be carried out in a manner which reduces or limits the bubble size associated therewith. To better understand bubble dissipation, one can model a string of contiguous bubbles as a 25 cylinder to look at the diffusion of the gas out of the "cylinder" into the surrounding fluid to analyze how the bubble volume or radius decreases with time. Presser et al., in modeling a simulation as stated above, noted that the bubble radius "r" versus time can be represented by the equation:

$$\frac{dr}{dt} = -K \Delta P / [r \ln (R/r)]$$

30 where "K" is Krogh's coefficient (the product of solubility "S" and diffusion coefficient "D" of the gas in the surrounding fluid), " ΔP " is the pressure difference

between gas in the bubbles and gas in the alveoli and "R" is the distance from the center of the bubbles to the inner edge of the adjacent alveoli. *See* Presser et al., *Fate of Air Emboli in the Pulmonary Circulation*, 67 J. Appl. Physiol. 5, pp. 1898-1902 (1989). To solve the equation requires numerical techniques, but the relationship can 5 be generally characterized as being substantially linear for air down to about a 10 μm radius bubble, at which size the rate of dissipation is increased (*i.e.*, it becomes steeper and more exponential-like). Presser et al. also notes that for air bubbles with radius' greater than about 10 μm , $dr/dt = -0.132 \mu\text{m/s}$. Thus, generally speaking, a 30 μm radius air bubble takes about 230 seconds to dissipate.

10 In contrast, as recognized by the instant invention, xenon bubble dissipation occurs at a faster rate than air. That is, for comparative analysis, it is believed that one can evaluate the Krogh's coefficient ($S \times D$) for Xe relative to air. The diffusion coefficient is substantially the same and can be cancelled out. For example, Xe in H_2O is about $1.9 \times 10^{-5} \text{ cm}^2/\text{s}$ while methane and water itself are at 2 and $2.3 \times 10^{-5} \text{ cm}^2/\text{s}$, 15 respectively. Thus, solubility "S" becomes the important factor. Therefore, approximating air as nitrogen, the solubility ratio of xenon gas to nitrogen gas in blood is (0.167/0.0148), or about eleven (11). Accordingly, the bubble dissipation rate (dr/dt) for xenon is estimated at $-1.5 \mu\text{m/s}$. The same 30 μm radius bubble will dissipate in about 20 seconds. This additionally supports the direct injectability of 20 ^{129}Xe polarized gas into systemic arterial and venous circulatory injection sites.

 Air bubbles of various sizes have been produced for injection into a coronary artery. *See* Van Blankenstein et al., *Heart Function after Injection of Small Air Bubbles in Coronary Artery of Pigs*, 67 J. App. Physiol. 5, pp. 1898-1902 (1989). In this study, air bubbles of 75, 150, and 300 μm diameter were formed with tolerances 25 of about 10 μm . Generally stated, a micropipette with a constant-pressure source of air was used to form the desired bubble size. Factors impacting the formation of bubble size were pipette diameter, air (gas) pressure, and the flow of fluid through the pipette (flow volume in the artery may also be parameter to be considered). It is anticipated that calibration curves can be generated based on these factors (*i.e.*, bubble-size 30 dependent variables) to generate the desired bubble size.

 In any event, in certain embodiments, the hyperpolarized ^{129}Xe gas can be directly injected into the subject, such as into the blood stream of the subject, in

bubble-sizes in the range of between 1nm to 300μm, and preferably in the range of between about 0.5-10μm.

In order to generate a series of sequential bubbles for injection, it is preferred that a frit or custom fabricated lumen (small diameter) configuration can be employed and/or with a controlled pressure set to form the desired bubble size (not shown). In certain embodiments, the frit may comprise glass (such as a substantially magnetically pure aluminosilicate or surface coated glass to reduce surface relaxation effects). A differently sized/configured frit (exit diameter/shape) or lumen may be formed for various injection sites (particularly to facilitate the production of smaller bubble size for arterial applications) and located such that it is in fluid communication with the conduit or even integrated into the syringe or IV or other catheter body itself.

In any event, a polarized ¹²⁹Xe gas injection quantity of as low as under 5 cc's, such as just 1-2 or 1-3 cc's, but typically at least about 14-20 cc's (depending upon the injection site), can provide improved signal strengths even over larger amounts with conventional hyperpolarized inhalation techniques (although greater quantities can be used as discussed above). For example, the brain-imaging example described above shows that an injection of just 1, 2, or 3 cc's of ¹²⁹Xe can result in larger signals than can be typically achieved through inhalation of 1 liter of hyperpolarized ¹²⁹Xe. The signal strength can be improved to be even stronger if isotopically enriched polarized ¹²⁹Xe is employed.

Furthermore, unlike injection of CO₂, the ¹²⁹Xe injection does not have to be performed at a rate which is fast enough to displace the blood. The ¹²⁹Xe can be readily imaged if it is (a) dissolved in the blood, or (b) if it remains (largely or in smaller amounts) in the gas phase as it travels in the bloodstream for imaging purposes.

In the case of an arterial injection where rapid dissolution of the xenon into the blood stream may be desired, the gas injection can be performed at a rate which is sufficiently slow so that the xenon can substantially dissolve into the blood stream as it is injected therein. Mathematically stated, this injection rate limit may be set at about

$$\frac{d}{dt}V_{xe} = \lambda Q$$

where “ λ ” is the xenon solubility in blood and “ Q ” is the volumetric blood flow rate in the vessel being injected. Injection at this speed can result in substantially fully xenon-saturated blood in the injection region. In certain embodiments, the injection rate can be selected such that it is less than the blood flow rate within the injection site. The injection rate can be carried out such that it is less than about 25-50% of the blood flow rate, particularly for arterial injection sites. For example, blood flow in the hepatic artery in an average adult is roughly 5.8cc/s, so it is anticipated that a xenon gas injection rate of about 1-5 cubic centimeter per second (cc/s), and in certain applications 2.9 cc/s or less, or in other applications about 1 cc/s or less should be physically tolerable and sufficiently rapid to deliver a quantity which can yield clinically acceptable NMR images and/or signals.

10 **Figure 4** illustrates three different flow rates and associated vessel diameters (at flow rates smaller than the hepatic artery described above (5.8 cc/s = 348 mL/min)). Of course, especially for more distal target imaging regions and/or smaller injection 15 quantities, or where is desirable to retain a larger portion of the gas non-dissolved in the bloodstream, faster injection rates can be employed.

15 Venous injections using even larger xenon volumes or quantities and/or more rapid ^{129}Xe injection rates (as well as larger bubble size) as compared to the arterial injection sites may also be suitable. For example, for 100 cc's of injectable gas, a 20 suitable injection rate can be about 2-3 cubic centimeters per second. In other applications, rates substantially equal to or less than about 2 cc/s may be appropriate. The injection rates can be controlled in a number of ways such as via manual or automated (or semi-automated) operation as will be appreciated by those of skill in the art. *See e.g.*, U.S. Patent No. 3,623,474 to Heilman et al. and U.S. Patent No. 25 5,322,511 to Armbruster et al. (describing power injection equipment). The contents of these documents are hereby incorporated by reference as if recited in full herein.

20 In contrast to inhalation methods, the gas-injection method allows smaller amounts of hyperpolarized gas to be effectively administered in smaller clinically effective doses. This smaller dose gas-based administration also allows for a 30 commercially advantageous use of isotopically enriched (typically more expensive formulation) polarized ^{129}Xe . “Isotopically enriched” means ^{129}Xe which has been enriched over natural levels (the natural level is about 26%). Preferably, the ^{129}Xe gas

which is polarized is enriched to a level which is isotopically enriched to at least about 50%, and more preferably enriched to at least about 70 %, and still more preferably enriched to at least about 80%.

The present invention now allows the arterial side of the pulmonary vessels to 5 be directly imaged rather than inferring or predicting ventilation defects vicariously as proposed in conventional inhalation based systems. That is, as discussed above, injection into a vein, allows the polarized gas to travel in the bloodstream through the heart and then into the pulmonary artery. In contrast, inhalation allows ventilation-based images and then as the polarized gas travels into the bloodstream through the 10 pulmonary vasculature, it travels into the pulmonary venous circulatory flow path and can allow signal information corresponding to the venous system.

Still further, the imaging techniques which employ direct injection of 15 hyperpolarized gas can provide perfusion images which are unobscured by ventilation defects typically associated with conventional inhalation-based images. That is, the inhalation methods may show a perfusion defect where a ventilation defect resides, because gas may be blocked from entering the vessels. In contrast, direct gas injection methods of the present invention can show “real” perfusion defects, *i.e.*, defects attributed (solely) to perfusion blockage. In addition, as noted above, using both 20 inhalation and injection delivery of polarized gas as described herein can provide complementary diagnostic information and detail.

It should also be noted that NMR imaging or signal acquisition of ^{129}Xe in the gas phase in the blood can provide increased an increased T_1 over that of the gas dissolved in the blood. In addition, ^{129}Xe dissolved into the blood may provide a broader spectrum attributed to the rapid exchange between the ^{129}Xe in RBC's and 25 plasma. Unfortunately, a broad spectral line typically translates to a relatively short T_2^* . Therefore, sizing and delivering the injectable dose so that it remains substantially as a gas in the bloodstream can allow longer data acquisition times and/or improved images or signals therefrom.

Of course, the injection rate or release rate (volume over time) can be selected 30 such the polarized gas is solubilized (substantially dissolved) into the blood proximate to the injection site. Alternately, the injection rate can be selected such that the gas is only partially or insubstantially solubilized in the blood proximate to the injection site

or such that it remains in a non-dissolved state for a longer period of time as it travels through the bloodstream. For example, introducing the hyperpolarized gas into a vein (through the walls of the vessel) such that it retains sufficient polarization to render a clinically useful gas-phase signal after about 8-10 seconds, and preferably after about 5 8-20 seconds, from the time of injection. Maintaining the hyperpolarized gas in the gas phase (such that it is not substantially dissolved into the bloodstream) can increase the T_1 of the gas in the body. This, in turn, can allow longer image acquisition times during which the signal can be picked up as a viable clinically useful diagnostic tool. Again, the venous injection sites can generally withstand a greater injection volume 10 and/or a greater delivery rate than a similarly sized arterial vessel.

Indeed, in the past, about 1ml of air in 10 ml of saline was injected into the right internal jugular (IJ) vein of a human and monitored with ultrasound for IJ valve competence. *See Ratanakorn et al., Jn. Of Neuroimaging, Vol. 9, pp. 10-14 (1999).* It is expected that about 1-10 ml of hyperpolarized ^{129}Xe gas, preferably configured with 15 reduced bubble sizes (preferably at about or less than 10 microns) injected into the IJ will also yield clinically useful images and/or spectra (the hyperpolarized xenon gas bubble dissipation being about 11 times faster than air in blood as discussed above).

Figure 1B schematically illustrates suitable injection sites (shown by asterisks located on the body and a corresponding circled letter) and an associated particular 20 tissue, organ, or vasculature target region (shown by dotted line box with and a corresponding letter identification) according to certain embodiments of the present invention.

	<u>Target Region of Interest</u>	<u>Preferred Injection Site</u>
25	Region A Cranium	Neck-Carotid Artery
	Region B Lower Extremities	Thigh-Femoral Artery
	Region C Pulmonary	Arm, Vein (preferably in conjunction with ventilated gas)
	Region D Renal (Kidneys)	Renal Artery
30	Region E Hepatic (Liver)	Hepatic Wedge
	Region A Cranium	Right internal jugular artery (IJ)

For example, as shown by the two circle "C" delivery sites, the pulmonary region preferably employs both an injection site to a vein in the arm to deliver gaseous ^{129}Xe and an inhalation delivery of polarized gas (the inhalation being either ^{129}Xe or ^3He , more preferably ^{129}Xe). Of course, the present invention is not limited to the 5 injection sites and target regions disclosed above, as additional or alternate sites and additional or alternative target regions can also be employed. Indeed, internal injection or release sites can also be employed such as through the use of special catheters (threaded to the desired injection or delivery site) to deliver gas phase ^{129}Xe to desired target regions as will be appreciated by one of skill in the art.

10 Certain embodiments of the present invention are directed to the use of injected gaseous polarized ^{129}Xe for the detection of pulmonary embolism. In these embodiments, the xenon is injected into a vein, preferably via an intravenous catheter inserted into a vein in the arm and, after a suitable delay, an image of the xenon in the arterial pulmonary circulation can be made to determine if an embolus is present. For 15 example, about 50-100 cc's of gas are injected and after about 5-25 second delay period, preferably about a 5-7 second image delay period (the delay period being measured from the time after injection stops) scanning is initiated. Preferably, the scanning, based on this injection, is completed in less than about 60 seconds, and preferably, in about 10-45, and more preferably in about 10-20 seconds.

20 Alternatively, a longer delay can be applied between the time of injection and the image data or signal acquisition or collection so that a scan can be made of the gaseous ^{129}Xe as it enters in the lung resulting from the venous injection, as the gaseous ^{129}Xe injected in a vein in the arm will subsequently dissolve only to appear or enter into the lung if circulation is not blocked in the pulmonary arteries. In 25 addition, even if the blockage is not severe enough to prevent the ^{129}Xe which is injected in gas phase from entering the lung, the signal intensity of this transitory ^{129}Xe in the lung can vary depending on the degree of restriction (brighter signal for smaller restrictions or free passage, and reduced signal intensity in the lung void space for blocked or substantially restricted blood circulation passages).

30 In certain embodiments, such as for the lung void space image, as is well known to those of skill in the art, suitable contrast mechanisms such as chemical shift, T_2^* , diffusion, etc., can be used to distinguish between imaging segments which

include the gaseous ^{129}Xe in the lung and versus (and preferably excludes or extracts) the signal data associated with the ^{129}Xe still dissolved in blood.

In certain embodiments, the pulmonary circulation image scan based on the gas injection is coupled with a ^{129}Xe or ^3He pulmonary ventilation scan. Using a 5 ^{129}Xe ventilation scan may be preferable, because it allows the same MRI transmit/receive coil to be used for the entire procedure. The ventilation scan can be employed regardless of the dissolution or lung based image rendering methods employed on the gaseous injected polarized ^{129}Xe . The coupled scan can identify a V/Q (volume versus flow rate in the circulatory system) mismatch and provide a 10 potential diagnostic tool for the clinician. Alternatively, if ^3He is used for the ventilation image, it is preferred that the chest coil be configured as a “double tuned” coil. That is, the double tuned coil is tuned to operate for both ^3He and ^{129}Xe operation.

In addition, it is preferred that the chest coils be configured to be “proton 15 blocked” allowing the MR scanner body coil to be used to make a proton image of the subject in substantially the exact same position as the subject during the V/Q image. Thus, the proton blocked chest coil allows the body coil to obtain supplemental proton-based data image (without the interference of the polarized gas based coil) which can be combined in a signal processor with the V/Q signal data to provide a 20 more detailed diagnostic evaluation of the target region of interest. Of course, the proton-blocked configuration of the gas based imaging coil can be operated with respect to the other gas-based images described herein.

In certain embodiments, the inhalation based image is generated using 25 polarized ^{129}Xe while the perfusion image is also generated using the injected gaseous polarized ^{129}Xe . An NMR system with a low field magnet may be used (such as about 0.1T-0.5T), and the pulmonary region image may provide increased signal intensity from the NMR resonance signals resulting from both the dissolved and gas phase xenon in the pulmonary region (two peaks, one associated with the RBC's and one with the plasma). Reduction of field strength can sacrifice chemical shift information 30 between the dissolved phase and gas phase xenon in the target region. Nonetheless, the advantage of low-field imaging of ^{129}Xe in blood is that the separate peaks of ^{129}Xe in RBCs versus plasma will overlap and yield a larger total signal than at high-

field where ^{129}Xe in blood or plasma is separately excited and imaged.

Alternatively, a larger field magnet (>0.5T) can be used which separately excites the dissolved phase and gas phase polarized gas present in the region of interest, and two or more data sets are captured via one or more excitation pulses

5 (such as two separate imaging sequences operated at two different excitation frequencies). In this embodiment, due to the chemical shift between the gas and dissolved phase resonance (approximately 200 p.p.m. at 1.5T), at least two images (both a perfusion and ventilation image) are generated on a patient during the same imaging session (“differential” imaging). A differential image can provide additional

10 diagnostic information over combined phase signals. For example, the differential image can help distinguish between a pulmonary embolus and a ventilation/perfusion defect associated with a structural anomaly as described above.

In operation, for MR images using ^{129}Xe as both the inhalation and perfusion medium, a first delivery of a first quantity of hyperpolarized gas can be administered

15 to a subject such as via injection. After a suitable, short, delay corresponding to the desired target imaging region (a delay corresponding to the time it takes the hyperpolarized gas to travel to the desired imaging site from the injection site), a scanning sequence can be initiated. For imaging the chest region (or regions affected by the position of the chest during breathing activities), it is preferred that the patient

20 hold his or her breath to help with locational co-registration between images (especially between injection based and ventilation based images). Image signal data associated with the injected polarized gas according to the present invention is obtained before the polarization of the gas has decayed to an undesirable level (preferably within about 1 minute, and more preferably within about 25 seconds from

25 the time of injection). One or more additional quantities of hyperpolarized ^{129}Xe can be subsequently injected as needed. That is, a series of small injections (or small releases to an *in situ* catheter) can be made which allow a corresponding series of data collection based on the image signal data associated therewith.

After the injected polarized gas has cleared the target region (or the

30 polarization has decayed to a point where it does not interfere with the ventilation image), the ventilation delivery can commence. That is, a second delivery of a second quantity of hyperpolarized gas is administered. Because the second delivery is an

inhalation delivery, the quantity of gas delivered is relatively large compared to the injectable quantity (about 0.75-1.5 liters versus less than about 20-100 cc's depending on the site). In operation, the subject inhales the second quantity and holds his or her breath (typically for about 15 seconds). In certain embodiments, the injection based and ventilation based MR images (or spectroscopic analysis) can be obtained during the same imaging session, reducing co-registration issues associated with relational positioning/re-positioning. In addition, separate (temporally spaced apart from the injections) breath-hold delivery cycles may be used for ventilation images and perfusion directed images, which can then be digitally combined with the injection signal data to provide a more complete image of the region.

In certain embodiments, where the pulmonary region is the target imaging region, the combined image may be based on at least two different administrations of polarized gas: (a) direct injection of polarized gas into a vein and (b) inhalation of polarized gas. These two different administrations can result in three different delivery mechanisms of polarized ¹²⁹Xe to the pulmonary (perfusion from the ¹²⁹Xe in the blood and tissues delivered from a venous injection to the arterial side of the circulatory system, perfusion into the vasculature from the inhaled gas delivered to the venous side of the circulatory system, and a ventilation image before, during, and/or subsequent to the perfusion image with the same or additional quantities of inhaled gas).

In any event, differential imaging can provide MR images with information which correlates to the total region (lung space, artery and vein, and boundary regions). This technique can produce MR images which allow diagnostic detection of emboli, perfusion defects, ventilation defects, and other circulatory and/or respiratory system problems in the pulmonary vasculature.

In addition, for studies used to evaluate pharmaceutical effectiveness, the gas may be injected without regard to the toxicity or survival outcome. Indeed, the injection of hyperpolarized ¹²⁹Xe into a specific target region can allow the efficacy of a pharmaceutical drug, compound, or mixture, or drug therapy aimed at a particular disease or organ function to be evaluated and/or confirmed (post mortem) that such drug is actually delivered to the appropriate site and/or that it has an influence on the targeted condition. For example, a treatment directed to cerebral disorders can be

evaluated for effectiveness in suitable animal studies by comparing the injected hyperpolarized- gas based image of the brain over time. Similarly the effectiveness of treatment on pulmonary or cardiac functions, blood flow, or neurological conditions and the like, may also be evaluated. In one example, targeted gene therapy directed to 5 increasing blood vessel growth at the heart can be delivered. Subsequently a quantity of ^{129}Xe gas can be injected to provide NMR signal based on the increased xenon associated with increased blood vessels at the target site to confirm the success of the directed gene therapy.

In addition, it is expected that small quantities of injected hyperpolarized ^{129}Xe 10 can provide additional safe and effective *in vivo* diagnostic assistance in evaluating the presence or absence of cancer in mammalian subjects, particularly humans (*i.e.*, cancerous tumor or benign cyst). For example, *in vivo* cancerous tumors can be characterized by the presence of increased random blood vessel growth (a condition known as angiogenesis). This is in contrast to benign cysts. Taking advantage of this 15 characteristic and the NMR signal information available using direct ^{129}Xe polarized gas injection, a target in an organ such as a tumor in a breast can be analyzed *in vivo*. In operation, a needle can be inserted or injected to the suspect region in the breast via conventional MR guided needle placement and ^{129}Xe can be released thereat (along with or in lieu of removing biopsy materials). Signature peaks in spectroscopy signals 20 can indicate the presence of cancer via the increased peak in the signal due to the increased blood (and xenon's solubility therein). In obtaining the signal or images, an appropriate field strength should be used so as to differentiate the peaks associated with xenon in blood versus xenon in fatty tissue as will be appreciated by one of skill in the art. Of course, other contrast mechanisms like chemical shift, T_2^* and the like, 25 can also be employed to exploit the ^{129}Xe image signal in the tumor.

Referring to **Figure 2**, in a preferred embodiment, a patient is positioned in a MRI system 25 and exposed to a magnetic field associated therewith. The MRI system 25 typically includes an NMR image processing system 26, a super-conducting magnet (not shown), gradient coils (with associated power supplies) (also not shown), 30 an excitation coil (transmit/receive RF coil) 30. Preferably, the coil 30 is configured as Helmholtz pairs oriented at 90 degrees relative to each other (not shown). Of course other configurations can also be used such as Helmholtz coil or a surface coil

for imaging near surface regions of the subject. The system also includes a RF amplifier for generating RF pulses set at predetermined frequencies (also not shown). For ^{129}Xe imaging at 1.5T field strength, the MRI imaging system 25 is set to operate in the gas-phase at about 17.6 MHz. For high field applications, the dissolved phase 5 excitation frequency is shifted below the gas phase excitation frequency. For example, the dissolved phase excitation frequency is shifted to be about 200 p.p.m. lower than the gas phase excitation frequency (corresponding to the chemical shift). Thus, at 1.5T, the dissolved phase ^{129}Xe RF excitation frequency is about 3.52kHz lower than the associated gas-phase excitation frequency. In yet another preferred 10 embodiment, the imaging method employs a 17.6000MHz gas phase excitation pulse and an associated dissolved phase excitation pulse of preferably 17.59648MHz. Of course, the magnet field strength and excitation frequency can vary as is well known to those of skill in the art.

In any event, in operation the RF pulse(s) is transmitted to the patient to excite 15 the nuclei of the polarized ^{129}Xe . The coil 30 is tuned to a selected frequency range and positioned adjacent the targeted imaging region to transmit the excitation pulses and to detect responses to the pulse sequence generated by the MRI imaging system 25. The coil 30 shown in **Figure 2** is positioned to image the pulmonary vasculature 20 region 12 (**Figure 1A**). Preferred coils 30 for standard chest imaging include a wrap-around coil with conductors positioned on both the front and back of the chest.

Examples of suitable coils known to those of skill in the art include a bird cage 25 configuration, a Helmholtz pair or quadrature Helmholtz pairs, a surface coil, and a solenoid coil. The RF excitation coil 30 is operably associated with the NMR image processing system 26 for exciting and transmitting image signal information from the polarized gas back to the NMR image processing system 26.

As noted above, once in position, the patient inhales a (predetermined) 30 quantity of polarized ^{129}Xe gas into the pulmonary region (*i.e.*, lungs and trachea). Preferably, after inhalation, the patient holds his or her breath for a predetermined time such as 5-20 seconds. This is described as a “breath-hold” delivery. Examples of suitable ventilation or inhalation delivered “single dose” quantities of polarized gases for breath-hold delivery include 0.5, 0.75, and 1.0 liters of gas. Preferably, the

dose at inhalation contains gas with a polarization level above 5%, and more preferably a polarization level above about 20%.

The MRI imaging system 25 shown in **Figure 2** includes a dual dose delivery system 38. Thus, as shown, the dual dose delivery system 38 preferably includes both an inhalation dose bag polarized gas supply 35 and an injectable gas dose ^{129}Xe supply 40. Preferably, a non-magnetic support 45 is employed to hold at least the inhalation dose(s) of polarized gas. The inhalation dose bag 35 is suspended from the support 45 and a length of polarization friendly conduit 37 is in fluid communication with the dose bag 35 and a mask 36 positioned over the airways of the subject, so that the subject can inhale the polarized gas, while positioned in the magnet, at the appropriate time. Preferably, the injectable dose 40 is preferably engaged with a catheter or IV 42, and is positioned proximate to the subject to reduce the conduit length 41 necessary to connect the gas to the catheter lumen 42 (IV) inserted into the subject. **Figure 5** illustrates an alternate injection site with the injected gas preferably delivered to the patient at a controlled rate, pressure, and a substantially controlled overall dispensed quantity.

One way to dispense the gas is to employ an inflatable bladder configured and sized to receive a major portion of the injected dose gas bag 40 (preferably configured to enclose the dose bag therein). In operation, at the appropriate predetermined dispensing time in the imaging cycle, a controller directs a compressor to fill the inflatable bladder to exert pressure onto the external walls of the flexible polymer dose bag. Air, gases or other fluids or liquids can also be used to expand the inflatable bladder. Preferably, for preservation of the polarization, deoxygenated water is used to reduce the migration of air into the dose bag. Of course, air can also be used, as the inflatable bladder is preferably configured with discrete channels which are formed of a magnetic contaminant-free material such as rubber, elastomers, or other expandable materials which will act as a shield between the bag walls and the air (*i.e.*, the air does not directly contact the exterior walls of the bag 40). Preferred materials for the dose bag are described in U.S. Patent No. 6,128,918 and co-pending and U.S. Patent Application Serial No 09/334,400, the contents of which are hereby incorporated by reference as if recited in full herein.

In any event, as the bladder expands, it increases the pressure it exerts onto the dose bag 40. Preferably, the bladder is symmetrically configured with discrete enclosed air (or gas or fluid) channels such that opposing channels contact opposing sides of the bag to facilitate a constant and substantially equal distribution of pressure 5 without the inflatable medium directly contacting the walls of the dose bag 40. In addition, instead of discrete channels 40C, the inflatable bag 40B itself can be sealed and inflate around the enclosed dose bag.

Also, whenever more than one delivery mechanism is employed to introduce polarized gas products to a subject, the MR imaging system 25 can be configured to 10 include an audible or visual alert to coordinate the dispensing of the substances.

Figures 6, 7A and 7B illustrate another embodiment of a syringe injection delivery system 75 according to the present invention. As shown, the syringe 90 includes a plunger 92, a primary chamber 94, capillary stem 115, and LUER LOK flow member 116 with a valve 117. As shown in Figure 6, the LUER LOK flow member 116 is connected on one side via the valve 117 to a vacuum system 118. The 15 valve configuration allows a vacuum to be introduced to pull unwanted oxygen from the chamber to prepare the container prior to gas introduction therein.

In the past, high purity/high grade nitrogen has been used to purge the oxygen from the hyperpolarized gas containers to reduce polarization losses attributed thereto. 20 According to a preferred embodiment of the present invention, CO₂ gas can be directed into the gas holding chamber and then removed via a vacuum introduced thereto in a “gas-evacuate” cleansing cycle. This CO₂ based gas-evacuate container preparation method can remove depolarizing oxygen from the containers. Further, even if residual traces of CO₂ remain in the chamber or passages, any CO₂ injected 25 with the hyperpolarized gas will be absorbed by the blood relatively quickly as noted above.

As the polarized gas contacts the primary chamber 94, the plunger 92, and the walls of the capillary stem 115 and lumen (during injection), it is preferred that they be configured from a polarization friendly material. As used herein, the term 30 “polarization friendly material” means materials which reduce the contact induced decay or relaxation associated therewith, such as materials which have reduced

solubility, permeability, or relaxivity values. Examples of suitable materials will be described further below.

Accordingly, it is preferred that the primary chamber 94 and at least the bottom primary surface 92B of the plunger (the gas contacting surface) be configured from a gas-contacting material which has a low relaxivity for ^{129}Xe . This material can comprise a high purity metal which is substantially free of ferrous and paramagnetic impurities. As shown in Figure 7A, the bottom surface of the plunger 92B is formed of a low-relaxivity material and a second peripherally (circumferentially) positioned seal 92S. *See* co-pending U.S. Patent Application No. 09/334,400 and 09/528,750, for a discussion of materials, containers, and gas delivery systems, the contents of which are hereby incorporated by reference as if recited in full herein. The sealing material can also be coated with a polarization friendly material or formed of materials and fillers with reduced depolarizing influence.

Exemplary materials for the interior surface of the primary chamber body and/or bottom surface of the plunger material (or other gas contacting surfaces such as capillary stems and conduits/catheters) includes certain polymers such as PE and nylon-6, and high purity glass (preferably high purity aluminosilicates) or quartz (or sol-gel coated surfaces (*see e.g.*, PCT US98/16834 to Cates et al., entitled *Sol-gel Coated Polarization Vessels*), and high purity metallized surfaces (substantially free of ferrous and paramagnetic impurities)). If high purity metal gas contacting surface materials are used, it is preferred that the high purity metal surface be formed from one or more of aluminum, gold, or silver. It is also preferred that any O-rings or seals used be coated with or formed from polarization-friendly materials to protect the gas from contacting potentially depolarizing fillers and other materials used in many commercially available seals. Of course, the lumen 42L (Figure 5) itself is also preferably formed such that at least the gas-contacting surfaces are coated with a high purity metal.

As noted above, in one embodiment, the syringe 90 also includes a capillary stem 115 which is configured to separate the primary gas chamber 94 of the syringe 75 from the valve 117 (to reduce the exposure to same because outer components such as the valve 117 or conduit 41 can potentially include depolarizing components). As such, the capillary stem 115 typically includes a reduced size diameter passage which

extends a distance between the chamber 94 and the LUER LOK flow member 116, valve 117, and other components. Preferably, the capillary stem 115 is formed of an aluminosilicate and is directly formed onto the end of the primary chamber 94. It is also preferred that the capillary stem 115 is sized with a length which is at least about 5 10% the length of the primary chamber, and more preferably at least 20% the length of the primary chamber. For example, for a 10 ml syringe having a chamber length of about 6 cm, the capillary stem has a corresponding length of about 6 mm. Of course, other configurations can also be used and the present invention is not considered to be limited thereto. For example, optimal or improved capillary stem sizing methods are 10 discussed further below.

In one embodiment, to obtain about a relatively long T_1 , the container 100 includes a primary gas holding chamber which has a chamber volume which is substantially larger than the volume associated with the capillary stem 115 (the chamber volume is preferably at least an order of magnitude greater volume than the 15 capillary stem volume). In this embodiment, the capillary stem is configured with a length which is about 6.9cm. One may also configure the radius of the stem such that is at, or less than, about 0.3 cm.

Thus, in producing the injectable product container, the syringe 75 can also be connected to the CO_2 source in conjunction with the vacuum source (or separately) to 20 direct CO_2 gas into the syringe along the passage 115P in the capillary stem 115 so as to run a series of several gas/evacuation or purge cycles to remove the oxygen and clean the chamber and capillary stem 115. The gas-evacuation preparation method will be discussed further below.

After the gas-evacuate cycle (or purge/pump cycles) the chamber 94 can be 25 finally evacuated and the valve 117 closed in preparation for filling with the hyperpolarized ^{129}Xe gas. Of course, the hyperpolarized gas can be directed into the syringe chamber 94 at a later time or at a time proximate to the evacuation step. In any event, once the desired volume of gas is directed into the syringe 75, the valve 117 can be closed and the syringe 75 transported to the patient. A catheter 42 can be 30 positioned and the lumen inserted into the patient in advance of engaging the syringe to the conduit and opening the LUER LOK flow member 116 to release the gas in to the *in situ* catheter 42 to deliver the gas at the appropriate time.

Figures 8A and 8B illustrate yet another system for controlling and/or dispensing hyperpolarized gas to a subject. Figure 8A illustrates a container 100 with a primary valve 110, a primary gas holding chamber 112, a capillary stem 115, and an expandable member 120. The primary valve 110 moves forward and rearward in response to rotation of the knob 110R to open and close the passage defined by the capillary stem 115 from the first port 116. A second entry port 125 is configured opposing the capillary stem 115 in fluid communication with the primary gas chamber 112. Preferably, a secondary valve 130 operates to open and close the second entry port 125. The expandable member 120 expands into the primary chamber 112 when the valve 130 is opened and fluid is introduced into the second entry port 125. The degree of expansion of the expandable member 120 corresponds to the quantity of fluid introduced through the second port 125. A liquid, gas, or mixture thereof can be used to expand the expandable member 120.

In one embodiment, the expandable member 120 defines a barrier between the polarized gas and the expansion medium; the expansion medium does not directly contact the polarized gas. Any suitable liquid or gas can be used as the expansion medium, and for thin barriers which may allow the medium to travel therethrough, nitrogen or deoxygenated water, or other substantially non-depolarizing fluids can be used as the expansion medium. In addition, because the expandable member does contact the polarized gas, it is preferred that it be formed of a polarization friendly (low relaxivity and low solubility) material for the polarized gas held therein. For example, a material such as LDPE or deuterated HDPE, or more preferably a high purity non-magnetic metal and the like, or other low-relaxivity material which has a low permeability for the hyperpolarized gas held in the chamber may be employed.

See co-pending Patent Application Serial Nos. 09/163,721 and 09/334,400. The contents of these documents are hereby incorporated by reference as if recited in full herein.

As shown in Figure 8B, after filling the container 100 at a fill site with a desired quantity of hyperpolarized gas such as ^{129}Xe through the first entry port 116, an injection means such as a matable conduit or chamber with a direct inject needle/lumen, catheter or IV needle 119, 42L is connected to the first entry port 116. In position, as shown the container 100 can be oriented on its side so that the length of

the delivery or polarized gas dispensing path “L” away from the container 100 can be reduced to reduce the potential exposure of the gas to contaminants as it travels therethrough. In the embodiment illustrated, a controller 22 directs an air compressor 47 to inflate the expandable member at a predetermined rate (preferably a constant rate). The primary valve 110 is opened and the polarized gas is allowed to exit the first entry port 116 at a controlled rate into the injection path and into the lumen 42L. In addition, the capillary stem 115 of the container is preferably configured such that once the gas is captured in the primary chamber 112, a major portion of the hyperpolarized gas in the container is isolated away from potentially depolarizing components (such as fittings, valves, and the like) during transport and/or storage as noted above. Of course, other flow control configurations can also be employed. For example, filling a container having a valve in fluid communication with tubing to about 2 atm with polarized ¹²⁹Xe. The valve can be opened and the pressure difference directs the gas into the tubing out of the container. Of course, over time, the flow rate due to the pressure differential will drop.

The capillary stem 115 can be formed as an integral part of the valve member 110 or as a separate component. For example, the valve 110 can include a body portion formed of glass such as Pyrex® or the like, and the capillary stem 115 can be directly formed onto an end portion of the valve 110. Alternatively, the capillary stem 115 can also be formed from a glass such as Pyrex® or an aluminosilicate, or other material to extend therefrom as a continuous body co-joined or fused to the lower portion of the valve 110. The valve illustrated in Figures 8A and 8B includes a plug portion 110P which longitudinally translates to engage with the lower nozzle end of the valve chamber 110N to close the flow path when the valve is in the closed position. In the reverse, the valve plug 110p moves away from the nozzle end 110n to allow the gas to flow through the capillary stem 115 and the and in (or out) the entry port 116.

Operationally, still referring to Figure 8B, the capillary stem 115 is configured such that a major portion of the hyperpolarized gas, once in the chamber 112, remains therein when the valve 110 is closed. That is, the dimensions and shape of the capillary stem 115 are such that diffusion of the hyperpolarized gas away from the container chamber 112 is inhibited. Thus, the capillary stem 115 can reduce the

amount of exposure for a major portion of the hyperpolarized gas with the valve 110 and any potentially depolarizing components operably associated therewith. In addition, the capillary stem 115 also provides a portion of the gas flow path 22f therethrough. As such, the capillary stem 115 includes an internal passage which is 5 preferably sized and configured in a manner which inhibits the flow of gas from the chamber 112 during storage or transport while also allowing the gas to exit the chamber 112 at its ultimate destination (injection site) without undue or significant impedance.

In sizing a capillary stem (which can be employed with any type of container 10 housing hyperpolarized noble gas (such as that shown in Figures 6 or 8A or otherwise)) to optimize the T_1 of the ^{129}Xe gas held therein, the following analysis can be used. Generally stated, T_1 can be represented by the following equation:

$$T_1 \approx \frac{V_{\text{main}} l_c}{2\pi R_c (DR_c + \psi l_c^2)}$$

15 Reviewing the equation, it will be appreciated that as $T_1 \rightarrow \infty$ as $R_c \rightarrow 0$. Thus, the "best" capillary radius is none at all. However, this is not practicable. Typically, a certain basic or minimum capillary radius is needed, *i.e.*, sufficiently sized, in order to allow gas to flow in and out of the capillary and for the main chamber to be successfully evacuated. In addition, some design limit can be placed on the "gas conductivity" of the capillary. This 20 aspect will be discussed further below. In any case, once a capillary radius or width has been chosen, the equation above can be used to determine an improved or "optimal" capillary length by differentiating the equation and setting it equal to zero. (Of course, the equations below can be used in the reverse to establish a desired radius based on a particular length).

25

$$\frac{dT_1}{dl_c} = 0$$

This yields a solution for the optimal capillary length represented by the following equation:

$$l_c = \sqrt{\frac{DR_c}{\psi}}$$

30 Note that this solution for l_c sets the diffusion component of relaxation in the capillary

equal to the surface-induced component of relaxation. Since the assumption of infinite depolarization rate at the end of the capillary is probably overstated, one can adjust (reduce) the determined or calculated capillary length a little shorter.

5 In order to calculate optimal capillary lengths, relaxivity values or estimates are needed. As a simple estimate, one can consider that an 180cc spherical chamber of GE180 glass has a relaxation times of about 40hr for ^3He and about 2hr for ^{129}Xe . Knowing the relationship of “ $A/V=3/R$ ” for a sphere, one can determine the relaxivity ψ of GE180 glass for both gases. The diffusion coefficients are noted for reference below.

Gas	T_1	ψ	D
^3He	40hr	$8.1 \times 10^{-6} \text{ cm/s}$	$2.05 \text{ cm}^2/\text{s}$
^{129}Xe	2hr	$1.7 \times 10^{-4} \text{ cm/s}$	$0.065 \text{ cm}^2/\text{s}$

10 The table above illustrates that optimal capillary lengths will be very different for ^{129}Xe with its smaller diffusion coefficient and much larger relaxivity than ^3He . Thus, this is preferably taken into account when designing the ^{129}Xe capillary stem.
15 For example, if we assume a 1mm capillary diameter, and use the values of relaxivity above, one can find the following:

	D	l_{opt}
^3He	$2.05 \text{ cm}^2/\text{s}$	111cm
^{129}Xe	$0.065 \text{ cm}^2/\text{s}$	4.4cm

Thus, for a ^{129}Xe syringe whose main chamber volume is about 20cm^3 , using a 4.4cm capillary of 1mm diameter can yield a capillary contribution to relaxation of $T_1 \approx 12\text{hr}$.
20 Double the capillary length would yield a T_1 of about 9.5hr, and half the capillary length would yield a T_1 of about 9.5hr. Figure 11 is a graph which illustrates an optimum capillary length (if one employs a stem with a length which is either larger or smaller than the optimal length, the T_1 is reduced over the T_1 obtainable at the optimal length)

25 In a preferred embodiment, the container 100 body (and the syringe body 94) is substantially formed from quartz glass gas contacting surfaces (high purity Si-O_2),

Pyrex®, aluminosilicate glasses such as GE180, CORNING 1720 or other long T_1 life silica based material. Transition glasses may be used to make a transition between glass materials having different thermal expansion coefficients. For example, for containers using multiple types of glass such as Pyrex®, body and GE180 stem or 5 other portion, a transition glass (such as Uranium glass (typically about 35% 235 U)) can be employed to join the two glasses and form the container. A suitable glass valve is available from Kimble Kontes Valves located in Vineland, NJ.

As is shown in **Figures 7B and 8B**, it is also preferred that a small excitation NMR coil 230 be positioned onto the container primary body 94, 112 and operably 10 engaged with the NMR image system 26 via a transmit/receive line 26T. The NMR excitation coil 230 can be in the flow path as shown or located on the side, proximate the exit path (shown as 230a in **Figure 8B**). This can allow a calibration measurement to be initiated just prior to dispensing the gas to the subject. Of course, the NMR coil 230 can be positioned in other locations along the body of the container, 15 and the calibration measurement can be taken prior to engagement with the controller 22 or the like. In any event, the injection dose containers of the present invention (such as item 100 in **Figure 8A**, items 35 and 40 in **Figure 2**, and item 75 in **Figure 6**) can allow transport of ^{129}Xe to the hospital from remote locations (by providing improved T_1 's) and can also enable calibration of the gaseous dosage just prior to 20 injection.

Figures 8C-8I illustrate alternate embodiments of an injection device according to the present invention. As shown in **Figure 8C**, an injector head 300 having a plurality of gas orifices 310 facing in the flow direction can be used to administer the hyperpolarized ^{129}Xe gas to the subject. The orifices 310 are sized and 25 configured so as to dispense the gas into the subject in a fine dispersion. In certain embodiments, in operation, the injector head 300 is configured to dispense a fine dispersion or spray of gas having microbubble sizes under about 50 μm , and preferably substantially between about 0.5-10 μm .

In certain embodiments, the orifices 310 may have an aperture width or 30 diameter of about 1nm-50 μm , and preferably a width which is about 10 μm or less such as between about 10nm-10 μm , between about 0.01-10 μm , or between about 0.01-1 μm to increase the surface area (and decrease the volume) of the bubbles

corresponding to the administered gas as it enters the tissue, blood, or selected region of the body. Decreasing the volume and increasing the surface area of the bubbles as they enter the blood stream may promote increased rates of ¹²⁹Xe dissolution into the blood (while inhibiting aggregation into undesirable large bubble sizes). A discussion 5 on certain aspects of nanojet configurations can be found in Moseler et al, *Formation, Stability, and Breakup of Nanojets*, Science, Vol. 289, No. 5482, pp. 1165-1169 (18 August 2000); the contents of which are hereby incorporated by reference as if recited in full herein.

10 The injector head 300 can be formed in or inserted into a distal end portion of an intravenous or intrarterial catheter 340 as shown in Figure 8D. The injector head 300 may also be positioned at other locations in the hyperpolarized gas flow path (such as at a position with is external of the body upstream of the entry point into the subject in the catheter or in a conduit connected thereto).

15 As shown in Figure 8D, the injector head 300 is in fluid communication with a source of hyperpolarized ¹²⁹Xe 350 and a pressure source 375. In operation, a constant or variable pressure forces the hyperpolarized ¹²⁹Xe to flow through the injector head 300 and out of the orifices 310 to form a gaseous dispersion at a point proximate the entry site of the subject. The constant or variable pressure can be generated with a pressure sufficient to provide a gas flow rate sufficient to create the 20 desired bubble size. Typical flow rates are as described above, such as about 3cc/s or less (which in certain embodiments administers the gas dose of about 60 cc's over a 20 second injection period). The variable pressure can be provided to generate a pulsatile flow (either via a step function operation or a ramped or gradual variation (increase and/or decrease) over time). The pressure source 375 may be a power 25 injector device, such as those which are well known to those of skill in the art. In operation, a rapid, controlled (pressure and volume) injection of gaseous hyperpolarized ¹²⁹Xe can be administered to the subject.

30 The injector head 300 can be formed into a conduit disposed between the (intravenous or intrarterial) catheter which is configured to pierce the skin of the subject or may be positioned or formed in the catheter itself as noted above.

In certain embodiments, the temperature of the hyperpolarized gas can be adjusted (heated or cooled) prior to ejection through the injector head 300. If cooled,

the temperature should be sufficient to assure that the gas remains in the gaseous state at injection. In certain embodiments, the hyperpolarized xenon gas can be heated so that it is at least 70 degrees F, and preferably in the range of about 98.6-105 degrees F, as it travels through the injector head orifices 310. The hyperpolarized gas can be
5 heated by exposing the captured gas to an elevated temperature as it travels along the flow path or by pre-heating a container holding the supply of ^{129}Xe prior to releasing the hyperpolarized gas into the administration exit flow path. Alternatively, or additionally, the injector head 300 may also be heated. In certain embodiments, heating methods and devices are selected so that, in operation, they do not
10 substantially negatively impact the polarization of the gas (a liquid heated immersion bath for the ^{129}Xe source container or a supplemental heating container positioned in the flow path, solar or light energy directed to the polarized gas, a flowable heated gas which is directed over the outer surface of the enclosed gas flow path, etc).

As shown in **Figures 8G and 8H**, the injector head 300 can be configured with
15 a convergent nozzle configuration. **Figure 8G** illustrates that the injector head 300 itself can have a convergent nozzle profile 301 to direct the gas from the flow path upstream thereof and into to the enclosed nozzle region and out of the orifices 310 positioned at the convergent end thereof. **Figure 8H** illustrates that the orifices 310 can be configured in the injector head 300 so that the individual orifices each define a
20 convergent nozzle, identified as a convergent nozzle orifice 310cn (decreases in area from the proximal end to the distal end along the axial direction of flow). Of course the injector head 300 may incorporate both features, convergent nozzle orifices 310cn with a convergent profile 301.

Figure 8I illustrates that the injector head 300 may include constant area
25 orifices 310ca as well as convergent area nozzle orifices 310cn. In other embodiments, the injector head 300 may be configured with a constant area body and/or the orifices 310 may be formed as only constant area orifices 310ca without convergent area nozzle orifices 310cn (not shown).

Figure 8G illustrates that the administration can be performed such that an
30 additive can be mixed *in situ* with the polarized ^{129}Xe to help form the fine dispersion formulation at ejection from the injector head 300. The additive is a pharmaceutical grade biocompatible substance which is substantially non-depolarizing to the

5 polarized ^{129}Xe gas. Examples of suitable substances may include blood, plasma, lipids, gases such as CO_2 or noble gases including non-hyperpolarized xenon, deuterated substances, or commercially available biomedical contrast agents. *See e.g.*, 10 60/014,321 and WO 97/37239 to Pines et al. and WO 99/52428 to Johnson et al., the contents of which are hereby incorporated by reference as if recited in full herein.

10 In certain embodiments, as shown in **Figure 8F**, the additive can be an emulsifier which is added to a mixing chamber 375 positioned upstream of the injector head 300 so that the emulsifier is mixed with the hyperpolarized gas to form an emulsified composition of gas as it is extruded or travels through the orifices 310 of the injector head 300. The emulsifier material can be selected such that it is flowable and is able to encapsulate the hyperpolarized gas to promote surface stabilization or to promote the fine dispersion of hyperpolarized gas into the blood. As shown in **Figure 8F**, the catheter or conduit 340 can be configured with two 15 separate flow channels 353, 354, which end into the enclosed mixing chamber 375 upstream of the injector head 300. The mixing chamber 375 may include baffles, a venturi, or other mixer components to promote the intermixing of the hyperpolarized gas with the emulsifier (or other additive).

20 As shown in **Figure 8E**, the hyperpolarized gas flow path 353 as well as the additive flow path 354, may include a flow meter 355,455, respectively, or other flow or volume measurement device. In certain embodiments, the additive is controlled so 25 that a substantially lesser amount of additive is used in comparison to the hyperpolarized gas (*i.e.*, 25-40% less than the volume of gaseous polarized ^{129}Xe). It is noted that the injection system and components described herein may also be suitable for dispensing other gases or agents such as hyperpolarized ^3He .

25 The gas contacting surfaces of the injector head 300 can be formed of or coated with suitable materials to inhibit the depolarization of the gas as it travels therethrough. Examples of suitable materials include, but are not limited to, alumminosilicate glass, certain polymer materials or metallic materials or other materials as described herein. Surface coatings, such as a sputter coating of a non- 30 depolarizing material of high purity silver or aluminum. The relaxivity of high purity aluminum for ^{129}Xe has been recently measured to be about 0.00225 cm/min. Metals other than aluminum which can be used include indium, gold, zinc, tin, copper,

bismuth, silver, niobium, and oxides thereof. Preferably, "high purity" metals are employed (*i.e.*, metals which are substantially free of paramagnetic or ferrous impurities) because even minute amounts of undesirable materials or contaminants may degrade the surface. Preferably, the metal is chosen such that it is well below 5 1ppm in ferrous or paramagnetic impurity content.

As noted above, because paramagnetic oxygen can be destructive to the polarization of the polarized gas, it is preferred that any syringe, dose bags or other gas containers or gas contacting components such as conduit, catheters, injector heads, mixing chambers, and the like, be preconditioned, *i.e.*, carefully cleaned of magnetic 10 impurities and purged of paramagnetic oxygen. That is, any gas contacting containers or surfaces are processed to reduce or remove the paramagnetic gases such as oxygen from within the chamber and container walls.

It is preferred that the containers be prepared as briefly discussed above. For containers made with rigid substrates, such as Pyrex®, UHV vacuum pumps can be 15 connected to the container to extract the oxygen. However, a roughing pump can also be used which is typically cheaper and easier than the UHV vacuum pump based process for both resilient and non-resilient containers. Preferably, for resilient dose bags, the bags are processed with several purge/pump cycles, *e.g.*, pumping at or below 20 mtorr for one minute, and then directing clean buffer gas (such as CO₂) into 20 the container at a pressure of about one atm or until the bag is substantially inflated. The oxygen partial pressure is then reduced in the container. This can be done with a vacuum but it is preferred that it be done with CO₂ (at least for the injection containers). Once the oxygen realizes the partial pressure imbalance across the container walls, it will outgas to re-establish equilibrium. Stated differently, the 25 oxygen in the container walls is outgassed by decreasing the partial pressure inside the container chamber. Typical oxygen solubilities are on the order of .01-.05; thus, 95-99% of the oxygen trapped in the walls will convert to a gas phase. Prior to use or filling, the container is evacuated, thus harmlessly removing the gaseous oxygen. Unlike conventional rigid containers, polymer bag containers can continue to outgas 30 (trapped gases can migrate to the chamber because of pressure differentials between the outer surface and the inner surface) even after the initial purge and pump cycles. Thus, care should be taken to reduce this behavior especially when the final filling is

not temporally performed near the preconditioning of the container. Preferably, for bags or resilient containers, a quantity of clean filler gas is directed into the bag (to substantially equalize the pressure between the chamber and ambient conditions) and sealed for storage in order to reduce the amount of further outgassing that may occur 5 when the bag is stored and exposed to ambient conditions. This should substantially stabilize or decrease any further outgassing of the polymer or container wall materials. In any event, the filler gas is preferably removed (evacuated) prior to final filling with the hyperpolarized gas.

It is also preferred that the container, syringe, conduit, catheter, injector 10 device, dose bag, or the like, be sterilized prior to introducing the hyperpolarized product therein. As used herein the term "sterilized" includes cleaning containers and contact surfaces such that the container is sufficiently clean to inhibit contamination of the product such that it is suitable for medical and medicinal purposes. In this way, the sterilized container allows for a substantially sterile and non-toxic hyperpolarized 15 product to be delivered for *in vivo* introduction into the patient. Suitable sterilization and cleaning methods are well known to those of skill in the art.

The injectable dose is configured as a smaller quantity gas phase product than the inhalation dose as described above. The inhalation dose can be mixed with other inert gases such as nitrogen or other biocompatible fluids to help disperse or atomize 20 the gas in the body (typically in the blood stream). As described above, subsequent to inhalation, at least a portion of the inhaled polarized gas enters into a dissolved state which enters the pulmonary arterial vasculature, including the boundary tissue, cells, membranes, and pulmonary blood vessels. Thus, a substantial amount of the dissolved polarized ^{129}Xe ultimately enters the blood stream with an associated 25 perfusion rate and cycles to the left atrium via the pulmonary vein, then to the left ventricle and out through the aorta.

Dissolved phase ^{129}Xe can have a relatively short relaxation time, T_1 , generally thought to be due to the presence of oxygen and due to paramagnetic deoxyhemoglobin in the blood compared to ^{129}Xe which remains in the gaseous phase 30 in the blood. In addition, even within a subject's own circulatory system different T_1 's will be exhibited. For example, T_1 for substantially fully oxygenated human cell membranes (the systemic arterial portion) will have a longer T_1 than the systemic

venous portion. That is, the T_1 of the polarized gas in the systemic venous portion will be less than the T_1 of the polarized gas in the systemic artery portion of the circulatory system which is more oxygenated than the systemic venous portion.

As is also known to those of skill in the art, the polarized ^{129}Xe also has an associated transverse relaxation time, T_2^* . In the bloodstream, the non-dissolved as well as the dissolved phase can have associated T_2^* which is acceptable to obtain signal or images. Indeed, the ^{129}Xe remaining as a gas in human blood will tend to exhibit longer T_2^* 's than that dissolved in human blood. Taking advantage of this characteristic, particularly for gas-phase based imaging (especially for T_2^* 's which are greater than at least about 30 milliseconds), multi-echo acquisition methods may be used. As will be appreciated by those of skill in the art, examples of suitable multi-echo methods include Echo Planar Imaging ("EPI"), Rapid Acquisition with Relaxation Enhancement ("RARE"), FSE ("Fast Spin Echo"), Gradient Recalled Echoes ("GRE"), and BEST. Examples of some suitable pulse sequences can be found in an article by John P. Mugler, III, entitled *Gradient-Echo MR Imaging*, RSNA Categorical Course in Physics: The Basic Physics of MR Imaging, 1997; 71-88. For example, the article illustrates an example of a standard single RF spin-echo pulse sequence with a 90 degree excitation pulse and a 180 degree refocusing pulse. G_p is a phase-encoded gradient, G_R is the readout gradient, G_S is the section-select gradient, and RF is the radio frequency. The article also illustrates a Gradient Recalled Echo pulse sequence (GRE) with a flip angle α and a Rapid Acquisition with Relaxation Enhancement (RARE) pulse sequence as well as a single shot Echo Planar Imaging (EPI) pulse sequence with gradient recalled echoes.

Figure 9 is a graph of one potential timing sequence which may be used and shows the delivery time of the injected gas (t_{inj}) and a MRI pulse imaging sequence according to one embodiment of the present invention. The imaging sequence illustrates a relatively long injection time during which a plurality of short small flip angle (below about 45 degrees, and more preferably below about 20 degrees) excitation pulses are directed at the target region. The excitation pulses begin shortly after the start of the injection ($t-t_1$) and end shortly after the injection ends ($t_{\text{end image}}$). In any case, the end of clinically useful signal generation associated with the injected hyperpolarized gas which is suitable for imaging is typically about 25 seconds after

the gas injection has ended, as the polarization of the gas has effectively decayed by this time. Of course, the choice of which flip angle and imaging procedure to use can depend on how many echoes can be done and how many phase encodes steps are pursued. For single echo acquisitions and increased (or optimal) SNR, having 128 5 phase encodes, a flip angle of about 5.1 degrees can be used.

It will be appreciated that at high magnetic field strength, it is possible to obtain increased image signal strength based on the dissolved phase direct injection polarized gas as well as the signal strength from gas phase ventilation in the lung. This can provide improved signal image resolution associated with the injected gas. It 10 will also be appreciated that there will be separate and distinctly resolvable excitation resonances associated with the (dissolved) versus ventilation (gas) imaging data signals. In contrast, at low magnetic field strengths, the separate resonances distinct at high fields, may overlap to provide an apparent increased image signal strength associated with both the dissolved and gas phase polarization.

15 Preferably, particularly for longer injection times (a delivery administered over a time which is greater than about 2.5 seconds), one or more small flip angle pulses can be employed to excite the polarized gas in the target region (such as the vasculature) to selectively destroy the polarization in a more localized image acquisition. As used herein, the term "small angle" means less than about 45 degrees.

20 Preferably, the gas injection sized quantities of hyperpolarized ¹²⁹Xe are formulated as isotopically enriched polarization gaseous products.

EXAMPLES

Figures 10A-10P are graphs of NMR spectra obtained about every 0.5 25 seconds with a 20 degree excitation pulse via a whole body imager based on about a 3 cc polarized ¹²⁹Xe gas injection into the vein of a rabbit (total of elapsed time from Figure 10A to 10P being about 8 seconds). The rabbit survived the experiment. The graphs illustrate that the gas remained substantially in the gas phase (substantially non-dissolved or insoluble in the bloodstream as it traveled through the bloodstream 30 during the image acquisition). The signal strength at 8 seconds (Figure 10P) being about 0.65 that of the original signal (Figure 10A). The rabbit was placed in a whole body imager so that the exact location of the signal within the rabbit's body is not

disclosed in the spectra. It is noted that a large quantity of the injected gas remained in the gas phase upon injection, most likely due to the size of the lumen used, about 0.5 mm.

It is also notable that the T_1 of the gas in the blood is relatively long, at least 5 about 20 seconds (for comparison, the T_1 of gas dissolved in blood is typically less than 20 seconds, such as about 4-6 seconds depending on oxygenation).

In summary, it is anticipated that diagnostic images can be obtained according to the present invention for desired target organs or systems, such as but not limited to, the kidneys, the brain or cranium region for cerebral assessment (grey/white 10 matter/blood), the liver, spleen, intestines, lower extremity blood circulation, tumor assessment (oxygen tension) and coronary artery restrictions/blood flow and other regions of interest.

The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. Although a few exemplary embodiments of this invention have 15 been described, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the claims. In the claims, means-plus-function clauses are intended to cover the structures 20 described herein as performing the recited function and not only structural equivalents but also equivalent structures. Therefore, it is to be understood that the foregoing is illustrative of the present invention and is not to be construed as limited to the specific embodiments disclosed, and that modifications to the disclosed embodiments, as well 25 as other embodiments, are intended to be included within the scope of the appended claims. The invention is defined by the following claims, with equivalents of the claims to be included therein.

THAT WHICH IS CLAIMED IS:

1. A method of screening for the presence of a pulmonary embolism, comprising the steps of:

positioning a subject having a pulmonary region and a blood circulation path including veins and arteries in an NMR system, the subject's pulmonary region having 5 pulmonary veins and pulmonary arteries and associated vasculature defining a pulmonary portion of the circulation path;

injecting a first quantity of polarized gaseous ^{129}Xe directly into at least one vein of the subject;

10 obtaining NMR signal data associated with the polarized ^{129}Xe in the pulmonary region of the subject, the signal data including information corresponding to the polarized gas introduced in said injecting step;

generating an MRI image having spatially coded visual representation of the NMR signal data; and

15 identifying the presence of at least one condition of blockage, restriction, abnormality, and substantially unobstructed free passage of the pulmonary circulation path.

2. A method according to Claim 1, wherein the quantity of injected polarized gaseous ^{129}Xe is less than about 100 cubic centimeters.

3. A method according to Claim 1, further comprising the step of controlling the rate of injection to less than about 3 cc/s at which the injecting step is performed to thereby control the delivery rate of the polarized gaseous ^{129}Xe into the vein.

4. A method according to Claim 2, wherein said injected quantity is less than about 20 cc's.

5. A method according to Claim 1, wherein said identifying step includes determining based on said injecting into the vein step whether the pulmonary

circulatory path is blocked or restricted based on the presence of polarized ^{129}Xe in the pulmonary arteries.

6. A method according to Claim 1, wherein said obtaining step includes obtaining NMR signal data associated with the presence of gaseous phase polarized ^{129}Xe in the lungs, the image signal intensity of which corresponds to the restriction, blockage or free passage of the pulmonary circulatory path.

7. A method according to Claim 6, wherein after said injection step, a portion of the injected polarized gaseous polarized ^{129}Xe travels along a portion of the pulmonary circulation path and subsequently enters the lung cavity in a quantity sufficient to provide NMR data with an associated signal intensity, a decreased signal intensity corresponding to the presence of a blockage or restriction in the pulmonary circulation path.

8. A method according to Claim 1, further comprising the step of administering the injection such that the gaseous polarized ^{129}Xe substantially dissolves into the vasculature proximate to the injection site.

9. A method according to Claim 8, wherein the controlled injection rate is less than about 2 cc/s.

10. A method according to Claim 1, wherein said injecting step is carried out such that a major portion of the gaseous polarized ^{129}Xe remains substantially as a gas in the bloodstream and exhibits a T_1 in the bloodstream which is greater than about 8 seconds.

11. A method according to Claim 1, wherein said NMR signal data obtaining step is performed in a low magnetic field, wherein the field strength is less than about 0.5T.

12. A method according to Claim 11, wherein the signal peaks associated

with the ^{129}Xe in plasma and the ^{129}Xe in red blood cells overlap to increase signal intensity associated therewith.

13. A method according to Claim 1, further comprising the step of introducing a second quantity of a polarized gas to a subject via inhalation during a single imaging session.

14. A method according to Claim 1, wherein said injection step is carried out intravenously.

15. A method according to Claim 14, wherein said injection step is carried out via a hypodermic syringe, and wherein said syringe includes gas contacting surfaces which are formed from polarization friendly materials.

16. A method according to Claim 13, wherein the second polarized gas comprises ^{129}Xe .

17. A method according to Claim 16, wherein said obtaining step includes the steps of:

5 exciting and receiving signal data associated with both the first and second quantities of ^{129}Xe with a single transmit/receive excitation coil; and

analyzing the NMR signal data associated with said exciting and receiving step in a way which distinguishes gaseous phase ^{129}Xe from the dissolved ^{129}Xe in said image generation step.

18. A method according to Claim 1, wherein said injection comprises multiple sequential injections thereby allowing for multi-shot MR imaging.

19. A method according to Claim 15, wherein the first quantity of polarized ^{129}Xe is isotopically enriched.

20. A method according to Claim 1, wherein said injected quantity of ^{129}Xe

includes a small amount of CO₂ therewith.

21. A method according to Claim 1, further comprising the step of introducing a quantity of surfactant into a subject proximate to the injection site of the ¹²⁹Xe.

22. A method according to Claim 1, further comprising the step of expelling the ¹²⁹Xe gas from a container into the subject during said injecting step such that the formation of large ¹²⁹Xe gas bubbles are inhibited during said injecting step.

23. A method according to Claim 22, wherein said expelling step configures the bubbles in sizes which are less than about 10 microns in diameter.

24. A method of enhancing the resolution of MRI-based medical images, comprising the steps of:

injecting directly into an injection site associated with a subject a first quantity of polarized ¹²⁹Xe in gaseous form during an NMR imaging session;

5 delivering a second quantity of polarized gas product to the subject within the same imaging session as said injecting step, the second quantity being larger than the first quantity; and

generating an MRI image corresponding to the excitation of the first and second quantities of polarized gas introduced in said injecting and delivering steps.

25. A method according to Claim 24, further comprising the step of introducing a surfactant to the vasculature of a subject such that the surfactant resides proximate to the injected ¹²⁹Xe.

26. A method according to Claim 25, wherein the injection site is associated with a portion of the systemic venous pulmonary vasculature.

27. A method according to Claim 25, wherein the injection site is

associated with a portion of the systemic arterial pulmonary vasculature.

28. A method according to Claim 24, wherein said injecting step is performed by injecting into a vein.

29. A method according to Claim 23, wherein said delivering step is performed by injecting to an artery.

30. A method according to Claim 24, further comprising the step of expelling the polarized ^{129}Xe gas from a container into the subject during said injecting step such that the formation of large ^{129}Xe gas bubbles are inhibited during said injecting step.

31. A method according to Claim 30, wherein said expelling step forms the ^{129}Xe into bubbles in sizes which are less than about 10 microns in diameter.

32. A method according to Claim 24, wherein said delivering step is performed by injecting the second quantity of hyperpolarized gas as a liquid into the subject.

33. A method according to Claim 24, wherein said delivering step is performed by injecting the second quantity of hyperpolarized gas as a gas.

34. A method according to Claim 24, wherein said delivering step comprises the steps of introducing via inhalation to the lungs the second quantity of hyperpolarized gas wherein a portion of the inhaled gas subsequently enters into pulmonary venous vasculature via perfusion uptake into the bloodstream and then 5 subsequently enters the pulmonary vein(s).

35. A method according to Claim 24, wherein said delivering step is carried out via a second injecting step and wherein the first quantity is less than about 20 cc's, and wherein the second quantity is less than about 100 cc's.

36. A method according to Claim 24, further comprising the step of administering the first quantity of polarized ^{129}Xe gas such that it substantially dissolves into the vasculature proximate to the injection site.

37. A method according to Claim 24, further comprising the step of administering the first quantity of polarized ^{129}Xe gas such that it remains substantially non-dissolved in the bloodstream and exhibits a T_1 of at least eight seconds therein.

38. A method according to Claim 24, further comprising the step of processing NMR signal data associated with both said injecting and delivering steps in a manner which distinguishes NMR signal information corresponding to gas phase versus dissolved gas signal information in said MRI image generating step.

39. A method according to Claim 24, further comprising the step of performing said generating step at a low magnetic field strength and acquiring the NMR signal data so that the signal peaks associated with the hyperpolarized ^{129}Xe in the red blood cells and plasma of the blood overlap.

40. A method according to Claim 34, wherein said administering step is carried out at an injection rate which is less than about 2cc/s.

41. A method according to Claim 24, wherein said injected first quantity of ^{129}Xe gas comprises trace amounts of CO_2 .

42. A method of obtaining diagnostic images of the cranial region, comprising the steps of:

injecting less than about 5cc's of ^{129}Xe polarized gas into an injection site in a carotid artery;

5 dissolving said polarized ^{129}Xe gas into the vasculature proximate to the injection site; and

generating an NMR image having signal intensity associated with the NMR excitation of the dissolved injected ^{129}Xe .

43. A method according to Claim 42, wherein said injecting step is performed in a manner which facilitates the dissolution of the gas in the vasculature proximate to the injection site.

44. A method according to Claim 41, wherein said injecting step is carried out in a manner which inhibits the bubble size associated with the injected ^{129}Xe from being larger than about 10 microns in diameter.

45. A method according to Claim 41, further comprising the step of injecting a quantity of a physiologically acceptable surfactant *in vivo* such that it is directed proximate to the injection site.

46. A method of facilitating bubble dissipation associated with the injection of polarized gaseous ^{129}Xe , comprising the step of introducing *in vivo* a physiologically acceptable surfactant temporally proximate to the *in vivo* injection of a quantity of hyperpolarized gas.

47. A method of obtaining an MR image, comprising the steps of:
injecting less than about 100 cc's of gaseous hyperpolarized ^{129}Xe *in vivo* into the vasculature of a mammalian subject; and
generating a NMR signal corresponding to the injected quantity of
5 hyperpolarized ^{129}Xe gas.

48. A method according to Claim 46, further comprising the step of administering the injection of the gas into the vasculature so that the gas is substantially dissolved into the vasculature proximate to the injection site.

49. A method according to Claim 46, further comprising the step of administering the injection of the gas into the vasculature so that the gas is

substantially non-dissolved into the vasculature proximate to the injection site.

50. A method according to Claim 47, wherein said injecting step is performed by injecting the hyperpolarized ^{129}Xe into at least one predetermined injection site chosen from the group consisting of a carotid artery, a pulmonary artery, a hepatic artery, and a renal artery.

51. A method according to Claim 47, wherein said injecting step is performed by injecting the hyperpolarized ^{129}Xe gas into at least one injection site chosen from the group consisting of a vein in the arm, a jugular vein, a pulmonary vein, a hepatic vein, and a renal vein.

52. A method according to Claim 47, wherein said injecting step is performed by injecting the hyperpolarized ^{129}Xe into at least two different injection sites, the sites chosen from the group consisting of a carotid artery, a pulmonary artery, a hepatic artery, a renal artery, a vein in the arm, a jugular vein, a pulmonary vein, a hepatic vein, and a renal vein.

53. A method according to Claim 47, wherein said injecting step comprises serially injecting quantities of ^{129}Xe gas during a predetermined imaging period to thereby allow multi-shot imaging.

54. A method according to Claim 47, further comprising the step of injecting a quantity of a physiologically acceptable surfactant *in vivo* such that it is directed proximate to the injected site.

55. A method according to Claim 47, wherein said predetermined injected quantity is less than about 20 cc's.

56. A method according to Claim 47, wherein said injecting step is carried out in a manner which inhibits the bubble size associated with the injected ^{129}Xe from being larger than about 10 microns in diameter.

57. A method according to Claim 47, wherein said injected ^{129}Xe gas comprises trace amounts of CO_2 .

58. A method according to Claim 47, wherein said injecting step comprises directing the hyperpolarized gaseous ^{129}Xe through an intravenous catheter positioned in the vein of a subject.

59. A method according to Claim 58, wherein said directing step comprises directing the hyperpolarized gas through an injector head comprising a plurality of outlet flow orifices formed therein to disperse the hyperpolarized gas into the blood stream of the subject.

60. A method according to Claim 59, further comprising the step of heating the hyperpolarized gas prior to said injecting step.

61. A method according to Claim 58, wherein the injector head includes at least one of a convergent nozzle profile and convergent nozzle orifices.

62. A method according to Claim 59, wherein said directing step comprises directing the hyperpolarized gas such that it flows into a mixing chamber prior to exiting from the injection head orifices.

63. A method according to Claim 58, further comprising the step of adding an emulsifier to the hyperpolarized gas in advance of the injecting step.

64. A method of evaluating the efficacy of targeted drug therapy, comprising the steps of:

delivering a quantity of a predetermined gene treatment preparation or pharmaceutical drug *in vivo* into a mammalian subject having a target site and a treatment condition;

injecting a predetermined quantity of gaseous phase hyperpolarized ^{129}Xe *in vivo* into a mammalian subject such that the hyperpolarized gas is delivered to the target site in gaseous or dissolved form;

10 generating a NMR image or spectroscopic signal of the target site associated with the injected hyperpolarized ^{129}Xe gas; and

evaluating the NMR image or spectroscopic signal to evaluate the efficacy of the gene treatment or drug on the treatment condition administered in said delivering step.

65. A method according to Claim 64, further comprising the step of acquiring at least two sets of data, the data representing two temporally spaced apart points in time, to evaluate if the treatment condition is influenced by the drug or gene therapy introduced in said delivering step.

66. A method according to Claim 64, further comprising the step of evaluating whether the drug is properly delivered to the target site.

67. A method according to Claim 64, wherein said at least two data sets correspond with a hyperpolarized ^{129}Xe gas NMR signal data acquisition obtained both before said delivering step and after said delivering step.

68. A method according to Claim 65, further comprising at least one of adjusting the quantity or formulation of the drug and confirming the proper delivery to the target site.

69. A method according to Claim 64, wherein the treatment condition is one of cancer, cardiac, renal, hepatic or pulmonary function, and cerebral function, and wherein the target site is selected so as to administer polarized ^{129}Xe gas to a region representative of that condition.

70. A method of determining the presence of cancerous tissue, comprising the steps of:

delivering a quantity of a pharmaceutical drug *in vivo* into a mammalian subject having a target site associated with a suspect mass or tissue abnormality;

5 injecting a quantity of gaseous hyperpolarized ^{129}Xe *in vivo* into a mammalian subject such that the hyperpolarized gas is delivered to the target site;

generating a NMR image or spectroscopic signal of the target site corresponding to the injected hyperpolarized ^{129}Xe gas; and

evaluating the NMR image or signal for the presence or absence of signature

10 patterns in the generated image or signal associated with the presence or absence of cancer.

71. A method according to Claim 70, wherein the suspect mass is a solid mass in the breast and said evaluating step determines *in vivo* the presence or absence of breast cancer.

72. An injectable ^{129}Xe gas product, said ^{129}Xe gas product formulated as a sterile non-toxic hyperpolarized gas formulation which consists essentially of isotopically enriched ^{129}Xe in gaseous phase which is injected *in vivo* in a quantity of less than about 20 cubic centimeters.

73. An injectable ^{129}Xe gas pharmaceutical grade product, said product formulated as a sterile non-toxic product which consists essentially of ^{129}Xe in gaseous phase and traces of CO_2 , wherein said injectable gas product is configured to be dispensed *in vivo*.

74. An syringe, comprising:

 a primary gas holding chamber having inner and outer surfaces;

 a plunger sized and configured to be received within said primary gas holding chamber, wherein said plunger has a gas contacting surface;

5 a quantity of hyperpolarized noble gas held in said primary gas holding chamber;

 a valve member operably associated with said primary gas holding chamber;

 and

a capillary stem positioned intermediate of said plunger and said valve
10 member in fluid communication with said primary gas holding chamber
wherein said primary gas holding chamber includes a wall having outer and
inner surfaces, and wherein said primary gas holding chamber inner surface and said
plunger gas contacting surface are formed from a material which inhibits contact
induced polarization decay associated therewith.

75. A syringe according to Claim 74, further comprising an NMR
excitation coil positioned proximate to said gas holding chamber such that in
operation it excites the hyperpolarized gas held within said syringe.

76. A syringe according to Claim 74, in combination with a length of
conduit and a catheter, wherein said conduit is operably associated with said valve and
said catheter is configured to be attached to a subject.

77. A syringe and catheter combination according to Claim 76, wherein
said conduit has opposing first and second end portions such that said second end
portion is proximate to said syringe gas holding chamber and said first end portion is
operably associated with a lumen configured for insertional engagement into the
5 vasculature of a subject to deliver said quantity of hyperpolarized gas thereto.

78. A syringe and catheter combination according to Claim 76, wherein
syringe and catheter are operably associated with a delivery path which is configured
to form bubbles with diameters which are less than about 150 microns.

79. A method according to Claim 74, wherein said delivery path is
configured to form polarized ^{129}Xe gas bubbles with diameters which are less than
about 10 μm .

80. A method of preparing a gas container having a sealable gas holding
chamber prior to the introduction of a polarized product therein, comprising the steps
of:

5 (a) evacuating the gas container;
(b) introducing a quantity of CO₂ gas therein; and
(c) repeating step (a) after step (b).

81. A method of sizing the length of a capillary stem on a container having a primary hyperpolarized gas holding chamber with a volume, the capillary stem having a volume which is substantially less than that of the gas holding chamber and includes a wall defining a flow channel aperture having a radius or width and a length, the wall having a gas contacting surface formed of a material having a relaxivity value for a selected hyperpolarized gas associated therewith, the method comprising the steps of:

- defining a capillary stem aperture size;
- determining the type of hyperpolarized gas to be held in the container and a diffusion coefficient associated therewith;
- establishing a relaxivity value for the material forming the capillary wall; and
- calculating an optimal capillary stem length.

82. A container having a primary gas holding chamber with a capillary stem, said capillary stem having a length defined by the method of Claim 81.

83. A container, comprising:

a primary gas holding chamber having a primary volume associated therewith;

a capillary stem having a wall with a gas contacting surface, a flow aperture, a length, and a capillary volume, said capillary stem in fluid communication with said gas holding chamber, wherein said gas contacting surface of said wall has a relaxivity value for a selected hyperpolarized gas associated therewith; and

5 a quantity of hyperpolarized gas held in said gas holding chamber;

wherein said capillary stem length is selected to substantially correspond to an optimal length to improve the polarization life of the hyperpolarized gas held therein,

10 and wherein the optimal length is calculated based on a desired T_1 , the width of the capillary flow aperture, and the relaxivity value.

84. A container according to Claim 83, wherein said primary chamber volume is about 20cm³, said capillary stem width is about 1 mm, said quantity of hyperpolarized gas comprises ¹²⁹Xe and said capillary stem length is about 4.4cm.

85. A container according to Claim 83, wherein said container has a capillary stem length which is longer when said gas is ³He than when said gas is ¹²⁹Xe.


5 86. An injection system for administering polarized gas to a subject, comprising:

a polarized noble gas supply;
a catheter configured and sized for intravenous or intrarterial placement in a subject in fluid communication with the supply of polarized noble gas; and
10 an injection head positioned in a distal portion of the catheter, wherein said injection head comprises multiple orifices having a width of between about 1nm-50μm, configured so that, in operation, hyperpolarized gas flows therethrough and out of the catheter into the subject.

15 87. An injection system according to Claim 86, wherein said injection head orifices are sized with a width between about 0.01-10 μm.

88. An injection system according to Claim 87, wherein said system further comprises an emulsifier source and a mixing chamber positioned intermediate
20 said orifices and said emulsifier and polarized gas sources.

1/14

FIG. 1A.

2/14








FIG. 1B.

3/14



SUBSTITUTE SHEET (RULE 26)

4/14

FIG. 3A.FIG. 3B.FIG. 4.

5/14




FIG. 5.

6/14





FIG. 7A.










FIG. 7B.


7/14



8/14

**FIG. 8C.****FIG. 8F.****FIG. 8I.****FIG. 8H.****FIG. 8G.**

9/14



10/14




FIG. 10A.




FIG. 10B.




FIG. 10C.




FIG. 10D.

11/14




FIG. 10E.




FIG. 10F.




FIG. 10G.




FIG. 10H.

12/14




FIG. 10I.




FIG. 10J.




FIG. 10K.




FIG. 10L.

13/14




FIG. 10M.




FIG. 10N.




FIG. 10O.




FIG. 10P.

14/14




FIG. 11.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/067955 A3

(51) International Patent Classification⁷: **A61B 5/055, A61M 5/14, G01R 33/28**

Downington, PA 19335 (US). **BROOKEMAN, James, R.** [US/US]; 1800 Dairy Road, Charlottesville, VA 22903 (US). **HAGSPIEL, Klaus, D.** [DE/US]; 395 Heron Lake, Charlottesville, VA 22903 (US).

(21) International Application Number: **PCT/US01/07812**

(74) Agent: **MYERS BIGEL SIBLEY & SAJOVEC, P.A.**; P.O. Box 37428, Raleigh, NC 27627 (US).

(22) International Filing Date: 12 March 2001 (12.03.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/189,072 13 March 2000 (13.03.2000) US


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (for all designated States except US): **MEDI-PHYSICS, INC.** [US/US]; 101 Carnegie Center, Princeton, NJ 08540 (US). **UNIVERSITY OF VIRGINIA PATENT FOUNDATION** [US/US]; 1224 West Main Street, Suite 1-110, Charlottesville, VA 22903 (US).

Published:
— with international search report

[Continued on next page]

(54) Title: **DIAGNOSTIC PROCEDURES USING DIRECT INJECTION OF GASEOUS HYPERPOLARIZED ¹²⁹XE AND ASSOCIATED SYSTEMS AND PRODUCTS**



WO 01/067955 A3

(57) Abstract: A method of screening for pulmonary embolism uses gaseous phase polarized Xe-129 which is injected directly into the vasculature of a subject. The gaseous Xe-129 can be delivered in a controlled manner such that the gas substantially dissolves into the vasculature proximate to the injection site. The injectable formulation of polarized Xe-129 gas is presented in small quantities of (preferably isotopically enriched) hyperpolarized Xe-129 and can provide high-quality vasculature MRI images or NMR spectroscopic signals with clinically useful signal resolution or intensity. The direct injection of small quantities of gas at particular sites along the vasculature targets specific target regions to provide increased signal intensity NMR images. The disclosure also includes related methods directed to other diagnostic vasculature regions physiological and conditions. Associated delivery and dispensing systems and methods, containers, and quantitative formulations of the polarized gas are also described.



(88) Date of publication of the international search report:
25 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Int'l Application No
EP/US 01/07812A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61B5/055 A61M5/14 G01R33/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61B G01R A61K A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 47940 A (MAGNETIC IMAGING TECHNOLOGIES INCORPORATED) 23 September 1999 (1999-09-23) page 4, line 6 -page 6, line 22 page 7, line 18 - line 28 page 23, line 6 -page 26, line 17 page 28, line 20 -page 29, line 14	72
A	---	73
X	WO 97 37239 A (LAWRENCE BERKELEY NATIONAL LABORATORY) 9 October 1997 (1997-10-09) cited in the application page 3, line 28 -page 5, line 33 page 9, line 37 -page 11, line 34 page 14, line 5 -page 15, line 17 page 16, line 28 -page 18, line 24 page 22, line 31 -page 23, line 38	72

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 March 2002

Date of mailing of the international search report

18. 04. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chen, A

INTERNATIONAL SEARCH REPORT

I International Application No
PCT/US 01/07812

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 033 645 A (UNGER ET AL.) 7 March 2000 (2000-03-07) abstract column 9, line 4 - line 28 column 10, line 18 - line 46 column 15, line 22 - line 35 column 29, line 9 - line 49 column 45, line 9 -column 46, line 37 ---	72,74,86
A	US 5 545 396 A (ALBERT ET AL.) 13 August 1996 (1996-08-13) cited in the application column 4, line 25 -column 5, line 37 column 8, line 41 -column 9, line 34 column 12, line 32 -column 14, line 33 ---	72,74
A	WO 99 07415 A (BRACCO RESEARCH S.A.) 18 February 1999 (1999-02-18) page 4, line 31 -page 6, line 5 ---	73
X	WO 99 66254 A (MAGNETIC IMAGING TECHNOLOGIES) 23 December 1999 (1999-12-23) page 5, line 24 -page 7, line 16 page 20, line 18 -page 21, line 25 page 24, line 8 -page 32, line 31 page 41, line 8 -page 42, line 17 figures 1,2,4,5,12A,B,13 ---	81,83
Y	ROSEN M S ET AL: "POLARIZED 129XE OPTICAL PUMPING/SPIN EXCHANGE AND DELIVERY SYSTEM FOR MAGNETIC RESONANCE SPECTROSCOPY AND IMAGING STUDIES" REVIEW OF SCIENTIFIC INSTRUMENTS, AMERICAN INSTITUTE OF PHYSICS. NEW YORK, US, vol. 70, no. 2, February 1999 (1999-02), pages 1546-1552, XP000879608 ISSN: 0034-6748 page 1547, right-hand column, line 3 -page 1550, right-hand column, line 11 figure 2 ---	74,80
Y	EP 0 446 715 A (E-Z-EM, INC.) 18 September 1991 (1991-09-18) column 5, line 14 -column 5, line 32 figure 3 ---	80
Y	US 5 968 017 A (LAMPROPOULOS ET AL.) 19 October 1999 (1999-10-19) column 13, line 41 -column 14, line 23 figures 12,13 ---	86
		-/-

INTERNATIONAL SEARCH REPORT

onal Application No
PCT/JS 01/07812

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 66255 A (MAGNETIC IMAGING TECHNOLOGIES) 23 December 1999 (1999-12-23) page 42, line 22 -page 46, line 32 page 57, line 11 -page 58, line 18 figures 7-9	83
A	---	72, 80-82,84
A	US 5 642 625 A (CATE, JR.ET AL.) 1 July 1997 (1997-07-01) cited in the application column 14, line 38 - line 40 column 15, line 50 -column 18, line 23 figure 3	74,80-83
A	EP 0 547 463 A (BECTON, DICKINSON AND COMPANY) 23 June 1993 (1993-06-23) column 1, line 3 - line 50 column 3, line 38 -column 4, line 39 figure 1	86,87
A	---	86,88
A	US 5 438 982 A (MACINTYRE) 8 August 1995 (1995-08-08) column 3, line 14 -column 4, line 19 figures	86,88
A	US 5 788 665 A (SEKINS) 4 August 1998 (1998-08-04) column 24, line 23 -column 26, line 16 figure 39	88

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/07812

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-23, 24-41, 42-63, 64-69, 70-71
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claim : 72

Gaseous hyperpolarized enriched $^{129}\text{Xenon}$ product.

1.1. Claim : 73

Gaseous hyperpolarized $^{129}\text{Xenon}$ product with traces of carbon dioxide.

2. Claims: 74-79

A syringe for delivering hyperpolarized $^{129}\text{Xenon}$.

3. Claim : 80

Method of preparing a gas container by flushing with carbon dioxide gas.

4. Claims: 81-82 and 83-85

Container for a hyperpolarized gas with a predetermined capillary stem size.

5. Claims: 86-88

Intravenous injection system for administering hyperpolarized gas to a subject with an injection head comprising multiple microscopic orifices.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 1-23,24-41,42-63,64-69,70-71

Rule 39.1(iv) PCT - Diagnostic methods and methods of imaging practised on the human or animal body comprising the surgical step of injecting a gaseous agent into the body and a methods of treatment by drug therapy also comprising the surgical step of injecting an agent before imaging the body.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/07812

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9947940	A	23-09-1999	AU CA EP WO US	3635699 A 2324269 A1 1066537 A1 9947940 A1 6346229 B1	11-10-1999 23-09-1999 10-01-2001 23-09-1999 12-02-2002
WO 9737239	A	09-10-1997	AU BR CA EP FI JP NO WO	2426697 A 9711082 A 2250401 A1 0890114 A1 982069 A 2001503646 T 984510 A 9737239 A1	22-10-1997 11-01-2000 09-10-1997 13-01-1999 10-11-1998 21-03-2001 27-11-1998 09-10-1997
US 6033645	A	07-03-2000	AU AU AU EP JP WO US US US	733492 B2 3313197 A 6188501 A 0930844 A1 2000513357 T 9748337 A1 2001051131 A1 6139819 A 6231834 B1	17-05-2001 07-01-1998 18-10-2001 28-07-1999 10-10-2000 24-12-1997 13-12-2001 31-10-2000 15-05-2001
US 5545396	A	13-08-1996	AU AU CA EP JP US WO US US US US	709515 B2 2278795 A 2183740 A1 0754009 A1 10501708 T 6241966 B1 9527438 A1 6123919 A 5789921 A 5785953 A 2001000726 A1	02-09-1999 30-10-1995 19-10-1995 22-01-1997 17-02-1998 05-06-2001 19-10-1995 26-09-2000 04-08-1998 28-07-1998 03-05-2001
WO 9907415	A	18-02-1999	AU AU CN EP WO JP NO US	726115 B2 8458798 A 1236323 T 0968000 A1 9907415 A1 2001501977 T 991688 A 6042809 A	02-11-2000 01-03-1999 24-11-1999 05-01-2000 18-02-1999 13-02-2001 09-06-1999 28-03-2000
WO 9966254	A	23-12-1999	AU AU BR BR CN EP EP WO WO US US	4572299 A 4686999 A 9911346 A 9912163 A 1312909 T 1090249 A2 1090250 A1 9966254 A1 9966255 A2 6269648 B1 2001025493 A1	05-01-2000 05-01-2000 13-03-2001 10-04-2001 12-09-2001 11-04-2001 11-04-2001 23-12-1999 23-12-1999 07-08-2001 04-10-2001

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/07812

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 446715	A	18-09-1991	US	5249579 A	05-10-1993
			AT	166777 T	15-06-1998
			AU	633406 B2	28-01-1993
			AU	7262991 A	12-09-1991
			CA	2037384 A1	10-09-1991
			CA	2037384 C	22-08-1995
			DE	69129505 D1	09-07-1998
			DE	69129505 T2	01-10-1998
			EP	0446715 A2	18-09-1991
			ES	2116271 T3	16-07-1998
			IL	97466 A	30-03-1995
			JP	2763966 B2	11-06-1998
			JP	4220269 A	11-08-1992
			US	5346470 A	13-09-1994
US 5968017	A	19-10-1999	AU	9802398 A	03-05-1999
			EP	1023094 A1	02-08-2000
			JP	2001519212 T	23-10-2001
			WO	9919008 A1	22-04-1999
WO 9966255	A	23-12-1999	US	6128918 A	10-10-2000
			AU	4572299 A	05-01-2000
			AU	4686999 A	05-01-2000
			BR	9911346 A	13-03-2001
			BR	9912163 A	10-04-2001
			CN	1312909 T	12-09-2001
			EP	1090249 A2	11-04-2001
			EP	1090250 A1	11-04-2001
			WO	9966254 A1	23-12-1999
			WO	9966255 A2	23-12-1999
			US	6269648 B1	07-08-2001
			US	2001025493 A1	04-10-2001
US 5642625	A	01-07-1997	AU	709623 B2	02-09-1999
			AU	2594397 A	22-10-1997
			CA	2250168 A1	09-10-1997
			EP	0896655 A1	17-02-1999
			JP	2000507689 T	20-06-2000
			WO	9737178 A1	09-10-1997
EP 547463	A	23-06-1993	US	5215527 A	01-06-1993
			DE	69229713 D1	09-09-1999
			DE	69229713 T2	02-12-1999
			EP	0547463 A1	23-06-1993
			JP	2076111 C	25-07-1996
			JP	5245210 A	24-09-1993
			JP	7114814 B	13-12-1995
US 5438982	A	08-08-1995	AT	192048 T	15-05-2000
			AU	674843 B2	16-01-1997
			AU	3788893 A	05-10-1993
			DE	69328477 D1	31-05-2000
			DE	69328477 T2	14-09-2000
			EP	0630272 A1	28-12-1994
			ES	2147753 T3	01-10-2000
			WO	9317744 A1	16-09-1993
US 5788665	A	04-08-1998	US	5562608. A	08-10-1996

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/07812

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 5788665	A	US	6242472 B1	05-06-2001
		US	6166092 A	26-12-2000
		US	5707352 A	13-01-1998
		AU	650845 B2	07-07-1994
		AU	4301389 A	08-04-1991
		AU	5628498 A	11-06-1998
		AU	683919 B2	27-11-1997
		AU	7448994 A	08-12-1994
		EP	0491685 A1	01-07-1992
		JP	2935519 B2	16-08-1999
		JP	5503855 T	24-06-1993
		WO	9103267 A1	21-03-1991
		US	5158536 A	27-10-1992